КОМПОЗИЦИОННАЯ КОЛЛАГЕНОВАЯ ГУБКА И СПОСОБ ЕЕ ИЗГОТОВЛЕНИЯ

Изобретение относится к медицине. Композиционная коллагеновая губка предназначена для остановки кровотечения, а также для стимулирования роста и пролиферации клеток. Губка содержит коллаген, факторы роста клеток и защитный агент в количестве 10%-50% масс., где защитный агент содержит аминокислоты, сахариды и альбумин в массовом отношении 1-11:1,25-17,5:1-7,5. Способ изготовления губки включает этап вирусной инактивации, который включает две стадии: первая стадия представляет собой вирусную инактивацию органическим растворителем/детергентом; вторая стадия представляет собой 30-120-минутную обработку раствора губки на водяной бане при 90-100°C, и ее проводят в присутствии защитного агента. Технический результат заключается в том, что губка имеет водопоглощающую способность более чем 52 раза на основании массы губки и имеет модуль упругости более 70,0 Н/см 2 . Губку можно подвергать вирусной инактивации в течение продолжительного времени при высокой температуре, в то время как биоактивность коллагена и факторов роста поддерживается. 2 н. и 5 з.п. ф-лы, 3 пр., 11 табл., 3 ил. РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (51) МПК A61L 15/32 A61L 15/44 A61K 38/18 A61K 47/12 A61K 47/26 A61K 47/42 (13) 2 584 348 C2 (2006.01) (2006.01) (2006.01) (2006.01) (2006.01) (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ (21)(22) Заявка: ИЗОБРЕТЕНИЯ К ПАТЕНТУ 2014103549/15, 07.06.2012 (24) Дата начала отсчета срока действия патента: 07.06.2012 (72) Автор(ы): ВАНЬ Шаньшань (CN) (73) Патентообладатель(и): ВАНЬ Шаньшань (CN) Приоритет(ы): (30) Конвенционный приоритет: (43) Дата публикации заявки: 10.09.2015 Бюл. № 25 R U 28.07.2011 CN 201110212713.0 (45) Опубликовано: 20.05.2016 Бюл. № 14 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 28.02.2014 2 5 8 4 3 4 8 (56) Список документов, цитированных в отчете о поиске: CN 101612113 A, 30.12.2009. WO 0137861 A1, 31.05.2001. US 5001169 A, 19.03.1991. WO 2004007707 A1, 22.01.2004. DE 4404625 C1, 13.04.1995. WO ...

ИНЪЕЦИРУЕМЫЕ КОМПОЗИЦИИ ДЕРМАЛЬНЫХ НАПОЛНИТЕЛЕЙ

BIOVERTRAEGLICHE UND BLUTVERTRAEGLICHE MATERIALIEN UND VERFAHREN ZU DEREN HERSTELLUNG

Element for implantation in body tissue, particularly bone tissue

In an element for implantation in body tissue, particularly bone tissue, consisting of a biologically flawless material with a micro-pitted surface, the pores in the surface have a diameter many times smaller than has been previously known in order to permit the occurrence of such a tight and extensive boundary zone around the implanted element that this achieves reinforced and inextricable anchoring in the tissue. The pore diameter may be as little as about 10 nm and as large as a few multiples of the normal diameter of the cells in the tissue, preferably no larger than the cell diameter, i.e. about 1000 nm. Optimal results are obtained with pore diameters equal to or smaller than about 300 nm and a finely pored rutile layer has been found to give a particularly strong and durable joint with the growing tissue. Preferably at least one deposit of an agent facilitating and/or accelerating the growing-together process is arranged on or in the element. The element may be shaped with grooves ...

Dosing regimens for treating hypoxia-associated tissue damage

Described herein are methods for the treatment of hypoxia-associated tissue damage in subjects. More particularly, the methods relate to treating hypoxia-associated tissue damage in a subject during a surgical procedure according to particular dosing regimens. Specifically, the methods concern a dosing scheme comprising dosing a subject during a surgical procedure wherein the first dose is administered to the subject within about 120 minutes following an initial surgical incision made during the surgical procedure.

Activated polymers binding biological molecules

The present invention relates to activated polymer substrates capable of binding functional biological molecules, to polymer substrates comprising bound and functional biological molecules, to devices comprising such substrates and to methods of producing them.

Hygiene tissue comprising a microbe-inhibiting composition

The present invention concerns hygiene tissue (1), such as a wet wipe, dry wipe, washcloth, patch, towelette, napkin, and the like comprising a microbe-inhibiting composition (8), said microbe-inhibiting composition (8) comprising an extracellular product of at least one probiotic bacterium and at least one additive in the form of an organic acid, with at least one of its pKa value not exceeding 5.5, and/or a salt thereof.

WOUND DRESSING MATERIALS

A wound dressing material comprising: a wound dressing carrier, N-acetyl cysteine or a salt or derivative thereof, and a stabilized ascorbate. Suitably, the stabilized ascorbate comprises an ascorbate-2-polyphosphate. Also provided are wound dressing comprising the materials, methods of treatment with the materials, and methods of making the materials.

PHARMACEUTICAL COMPOSITIONS FOR PROMOTING HEALING OF WOUNDS

The invention relates to pharmaceutical compositions in the form of semi-solid aqueous gels for use in wound alimentation by application to a wound during healing. The compositions contain in solution each of the essential and semi-essential amino acids and malic acid and have a pH in the range 6.5 to 8.

MEDIUM AND MATRIX FOR LONG-TERM PROLIFERATION OF CELLS

A cell culture medium and hydrogel matrix for long term storage and proliferation of cells is provided. The cell culture medium and hydrogel matrix may include an effective amount of polar amino acids, the polar amino acids selected from the group consisting of arginine, lysine, histidine, glutamic acid, and aspartic acid. One embodiment of the cell culture medium comprises about 5 to about 150 mM of polar amino acids. The hydrogel matrix comprises about 3 to about 150 mM of polar amino acids. L-arginine and L- glutamic acid are preferably supplemented in the cell culture medium. L- arginine, L-lysine, and L-glutamic acid are preferably supplemented in the hydrogel matrix. A method of maintaining viability and functioning of a transplant is also provided. The method of maintaining viability of a transplant includes encapsulating the cells in a hydrogel matrix and injecting the encapsulated cells into the host organism. The matrix of the present invention may also be used to promote vascularization ...

DOSING REGIMENS FOR TREATING HYPOXIA-ASSOCIATED TISSUE DAMAGE

Described herein are methods for the treatment of hypoxia-associated tissue damage in subjects. More particularly, the methods relate to treating hypoxia-associated tissue damage in a subject during a surgical procedure according to particular dosing regimens. Specifically, the methods concern a dosing scheme comprising dosing a subject during a surgical procedure wherein the first dose is administered to the subject within about 120 minutes following an initial surgical incision made during the surgical procedure.

BROAD SPECTRUM ANTIMICROBIAL & ANTICOAGULANT COMPOSITION

To reduce problems associated with clotting and thrombus formation, it is now common to "lock" intravascular access catheters between successive uses. Locking typically involves first flushing the catheter with saline to remove blood and other substances from the catheter lumen. After the catheter has been flushed, an anti¬ coagulant solution is injected to displace the saline and fill the lumen. Use of an effective antimicrobial substance along with anticoagulant during the same process is important to reduce the possibility of bacterial contamination and subsequent infection. The present invention deals with a safe, effective and economical catheter lock flush solution with excellent antimicrobial and anticoagulant activity. The unique ratio of the active components of the catheter lock solution used in the invention i.e. Sodium salt(s) of EDTA, Ethanol and D-mannitol with a suitable pH ensures broad-spectrum antimicrobial and optimum anticoagulant activity.

HAEMOSTATIC MATERIAL

The present invention relates to a haemostatic material which is effective at controlling the flow of blood from both standard and coagulopathic wound injuries, whilst maintaining a reduced compression time, minimising the requirement for resuscitation fluids, and being easy and safe to use.

DRESSING AND A METHOD FOR THE MANUFACTURE THEREOF

WOUND PACKING MATERIAL COMPRISING CHEMOEFFECTOR

A wound packing material, particularly suitable for use in negative pressure wound therapy, comprising a porous material admixed with a chemoattractant. This disclosure further provides methods of manufacturing the wound packing material, and therapeutic methods of using the wound packing material.

MODIFIED OSTEOGENIC MATERIALS

A process and product comprising collagen and demineralized bone particles. The product may contain a maximum of 20 % by weight inorganic materials. The product may be densified by compression. Additional osteogenic factors, mitogens, drugs or antibiotics may be incorporated therein. Inorganic materials may be bound to the organic matrix via precoating with a calcium or hydroxyapatite binding protein, peptide or amino acid. The materials also display long lasting drug release characteristics. The subject of this invention is a process and resultant composition which increases the rate and predictability of osteoinduction by demineralized bone matrix. In particular, this invention relates to compositions of demineralized bone and calcium or other mineral salts which exhibit enhanced osteogenic potential. This invention further relates to osteogenic compositions comprising between about 60 % to 90 % demineralized bone by weight and to compositions comprising a carrier and alkaline phosphatase ...

PHARMACEUTICAL COMPOSITION FOR ACCELERATING THE HEALING OF WOUNDS.

ELEMENT FOR IMPLANTATION INTO KOERPERGEWEBE.

PHARMACEUTICAL AND COSMETIC COMPOSITIONS FOR ACCELERATION OF HEALING PROCESS WOUNDS AND OTHER SURFACE DAMAGES

THREE-DIMENSIONAL PERMEABLE MATTER OF WIDE SURFACE

Structure poreuse perméable tridimensionnelle. Elle comporte des canaux ou trajets d'écoulement tridimensionnels séparés interpénétrants. Chacun d'eux est un système fermé à pores communicants et s'interpénètre avec la structure. Applications notamment biomédicales. Three-dimensional permeable porous structure. It has separate interpenetrating three-dimensional flow channels or paths. Each of them is a closed system with communicating pores and interpenetrates with the structure. Applications including biomedical.

ACTIVE SUBSTANCE-RELEASING WOUND DRESSING

The invention relates to a wound dressing, comprising a liquid-absorbing substrate having active substance depots contained therein, wherein the active substance depots comprise particles of at least one active substance which are encapsulated in a silicone shell. The invention further relates to a wound dressing according to the invention for use as a means for treating wounds and to the use of a wound dressing according to the invention for producing a means for treating wounds.

ABSORBENT PRODUCTS WITH ANTI-BACTERIAL AND ANTI-ODOUR PROPERTIES

A disposable absorbent hygiene product is provided, comprising an absorbent core disposed between a liquid pervious topsheet intended to face the wearer, and a backsheet intended to face away from the wearer, wherein said absorbent core comprises a super absorbent polymer composition that comprises a) super absorbent polymer particles including a cross-linked polymer of a water soluble ethylenically unsaturated monomer containing an acidic group, at least a part of said acidic groups being neutralized; and b) a particle size-controlled antibacterial agent that comprises a chelating agent containing EDTA or an alkali metal salt thereof; a mixture of an organic acid and a silicate-based salt; and a particle size control agent.

Fiber product having antibacterial and deodorant function

According to the present invention, a cellulose fiber or a fiber product made of said cellulose fiber is contacted with a basic amino acid ester and thereafter heat treated, thereby there may be provided an antibacterial product which does not lose its antibacterial property even by being washed several times. The fiber product is excellent in antibacterial property, deodorant property and safety and suitable for use as an antibacterial product such as socks, towel or the like which especially an odor becomes a problem due to the propagation of bacteria during using or storing it, and further it is suitable for use as a medical or sanitary article.

EPSILON-POLY-LYSINE CAPSULES

The present disclosure relates to capsules having a core and one or more capsular walls surrounding the core, wherein at least one of the capsular walls comprises a polymer comprising epsilon-poly-lysine or a derivative thereof.

АНТИМИКРОБНЫЕ КОМПОЗИЦИИ

COATED IMPLANT

Pharmaceutical compositions containing amino acids for promoting the healing of wounds

The invention relates to pharmaceutical compositions in the form of semi-solid aqueous gels for use in wound alimentation by application to a wound during healing. The compositions contain in solution each of the essential and semi- essential amino acids and malic acid and have a pH in the range 6.5 to 8.

Medical article

USE OF ANTIFIBRINOLYTIKA FOR THE PREPARATION AND THE PRODUCTION OF TUPFERN, KOMPRESSEN OR PLASTERS

METHODS FOR THE IMPROVEMENT OF THE VASKULARISIERUNG AND PROMOTION OF THE CICATRISATION

METHOD FOR THE REDUCTION OF THE IMMUNE IDENTIFICATION

ELEMENT FOR IMPLANTATION IN BONE FABRICS

Method of obscuring immune recognition

Modified osteogenic materials

Medium and matrix for long-term proliferation of cells

Biofunctional fibers

Wound packing material comprising chemoeffector

A wound packing material, particularly suitable for use in negative pressure wound therapy, comprising a porous material admixed with a chemoattractant. This disclosure further provides methods of manufacturing the wound packing material, and therapeutic methods of using the wound packing material.

Antimicrobial compositions

An anti-microbial composition, comprising a chelator (such as EDTA and its salts), and a transport enhancer (such as Methyl Sufonyl Methane; MSM) is provided. Together, the combination of the two substances unexpectedly and beneficially inhibits bacterial or fungal biofilms when administered to an area of microbial infection. Preferred formulations include spray, lotion, solution, gel, cream, ointment, soap, deodorant, surgical rinse, or dental rinse.

DRESSING AND A METHOD FOR THE MANUFACTURE THEREOF

The invention relates to a dressing which incorporates substance for cleansing sores and stimulating the healing thereof. The substance is zinc oxide, which is bound in the dressing with the aid of a tissue compatible polymer. The invention also relates to a method for preparing such dressings.

DELIVERY SYSTEMS FOR ADMINISTRATION OF CATIONIC BIOLOGICAL ACTIVES

A Delivery System for delivery of an Active Component is provided. The Delivery System comprises a Delivery Matrix and an Active Component. The Delivery Matrix has one or both of (i) a Cationic Component; and (ii) a Matrix Forming Substance. The Cationic Component has one or both of: (i) a cationic polymer or cationic copolymer, and (ii) a positively charged non-polymeric compound or composition. The Active Component comprises a cationic bioactive. The Delivery Matrix has a mEq amount of positive charge which is equal to or exceeds the mEq amount of positive charge of the Active Component. The Delivery Matrix may comprise chitosan, or other biopolymers, synthetic polymers, matrix polymers and large molecules, which themselves are matrix forming, or are combined with a Matrix Forming Substance and one or more other Cationic Components to form the positively charged Delivery Matrix.

WOUND PACKING MATERIAL COMPRISING CHEMOEFFECTOR

A wound packing material, particularly suitable for use in negative pressure wound therapy, comprising a porous material admixed with a chemoattractant. This disclosure further provides methods of manufacturing the wound packing material, and therapeutic methods of using the wound packing material.

PROCESS FOR PREPARING BIOABSORBABLE SHEET PREPARATION HOLDING THROMBIN

Provided is a method of producing a bioabsorbable sheet preparation which comprises thrombin having been im-mobilized thereon. A method of producing a thrombin-immobilized bioabsorbable sheet preparation which comprises steps of dip-ping a bioabsorbable sheet comprising polyglycolic acid in a filling solution containing thrombin as the active ingredient, glycerol as a softening agent and Tween 80 as an infiltrating agent, optionally together with histidine and trehalose as stabilizers, drying the same and thus immobilizing thrombin on the bioabsorbable sheet as described above; and a thrombin-immobilized bioab-sorbable sheet preparation obtained by the preceding method.

MICRONEEDLE DEVICE HAVING A PEPTIDE THERAPEUTIC AGENT AND AN AMINO ACID, METHODS OF MAKING AND USING THE SAME

A medical device including an anay of microneedles and a coating disposed on or within the microneedles and a method of making such a device are disclosed. The coating includes a peptide therapeutic agent and an amino acid. A method of stabilizing a peptide therapeutic agent with an amino acid on an array of microneedles is also disclosed. In some cases, the peptide therapeutic agent and the amino acid either both have a net positive charge or both have a net negative charge. In some cases, the peptide therapeutic agent is histidine.

COMPOSITIONS PHARMACEUTIQUES ACCELERANT LA GUERISON DE BLESSURES

COMPOSITIONS PHARMACEUTIQUES POUR ACCELERER LA GUERISON DE PLAIES ET DE BLESSURES. CES COMPOSITIONS SONT CONSTITUEES D'UN MELANGE DE TOUS LES ACIDES AMINES ESSENTIELS ET SEMI-ESSENTIELS ET DE L'ACIDE MALIQUE SOUS FORME D'UN GEL AQUEUX SEMI-SOLIDE D'UN PH DE 6,5 A 8, PREPARE A L'AIDE D'UN AGENT GELIFIANT TEL QU'UNE SUBSTANCE CELLULOSIQUE, UN POLYSACCHARIDE OU LA POLYVINYLPYRROLIDONE. APPLICATION EN MILIEU CLINIQUE ET CHIRURGICAL.

MATIERE PERMEABLE TRIDIMENSIONNELLE DE SURFACE ETENDUE

Structure poreuse perméable tridimensionnelle. Elle comporte des canaux ou trajets d'écoulement tridimensionnels séparés interpénétrants. Chacun d'eux est un système fermé à pores communicants et s'interpénètre avec la structure. Applications notamment biomédicales.

PHARMACEUTICAL COMPOSITIONS ACCELERATING THE CURE OF WOUNDS

COMPOSITIONS PHARMACEUTIQUES POUR ACCELERER LA GUERISON DE PLAIES ET DE BLESSURES. CES COMPOSITIONS SONT CONSTITUEES D'UN MELANGE DE TOUS LES ACIDES AMINES ESSENTIELS ET SEMI-ESSENTIELS ET DE L'ACIDE MALIQUE SOUS FORME D'UN GEL AQUEUX SEMI-SOLIDE D'UN PH DE 6,5 A 8, PREPARE A L'AIDE D'UN AGENT GELIFIANT TEL QU'UNE SUBSTANCE CELLULOSIQUE, UN POLYSACCHARIDE OU LA POLYVINYLPYRROLIDONE. APPLICATION EN MILIEU CLINIQUE ET CHIRURGICAL. PHARMACEUTICAL COMPOSITIONS TO ACCELERATE THE HEALING OF WOUNDS AND INJURIES. THESE COMPOSITIONS CONSTITUTE A MIXTURE OF ALL ESSENTIAL AND SEMI-ESSENTIAL AMINO ACIDS AND MALIC ACID IN THE FORM OF A SEMI-SOLID AQUEOUS GEL WITH A PH OF 6.5 TO 8, PREPARED WITH AID OF A GELIFIER SUCH AS A CELLULOSIC SUBSTANCE, A POLYSACCHARIDE OR POLYVINYLPYRROLIDONE. APPLICATION IN CLINICAL AND SURGICAL SETTINGS.

АНТИМИКРОБНЫЕ КОМПОЗИЦИИ

FIELD: medicine. SUBSTANCE: group of inventions refers to medicine and aims at inhibiting or treating bacterial or fungal infections. Antimicrobial composition contains a chelating agent or salts thereof, methylsulphonylmethane (MSM) and an acceptable carrier or base for such compositions. Chelating agent contains from about 0.1 % to about 15 % (weight/weight), transport agent - from about 0.1 % to about 40 % (weight/weight), ratio of chelating agent and MSM is from about 10:1 to about 1:20. Methods are provided for suppressing bacterial infections associated with biofilms, inhibiting contamination of a medical or surgical instrument with bacteria or fungi, facilitating separation of bacterial or fungal cells from biofilm, suppression or treatment of bacterial or fungal infections, including introduction or contact with said composition. Invention also provides a medical device, a dressing material, a transdermal plaster, a personal cleansing composition for personal hygiene and an oral rinse agent containing said composition. EFFECT: using the group of inventions enables effective control and inhibition of biofilm formation in medical and industrial applications. 46 cl, 1 dwg, 4 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 694 758 C2 (51) МПК A61K 31/4706 (2006.01) A61P 31/04 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК A61K 31/4706 (2019.02); A61K 2121/00 (2019.02); A61P 31/04 (2019.02) (21)(22) Заявка: 2015129833, 20.12.2013 (24) Дата начала отсчета срока действия патента: Дата регистрации: Приоритет(ы): (30) Конвенционный приоритет: 20.12.2012 US 61/740,396 (43) Дата публикации заявки: 25.01.2017 Бюл. № 3 (45) Опубликовано: 16.07.2019 Бюл. № 20 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 20.07.2015 (56) Список документов, цитированных в отчете о поиске: WO 2006135854 A2, 21.12.2006. WO 2007068938 A2, 21.06.2007. US 2010062974 A1, 11.03.2010. US 2008038219 A1, 14.02.2008. US ...

НЕВПИТЫВАЮЩИЕ И ВПИТЫВАЮЩИЕ ИЗДЕЛИЯ ПОДАВЛЕНИЯ ВЫРАБОТКИ ЭКЗОПРОТЕИНОВ

... 1. Ингибитор экзопротеина для подавления выработки экзопротеинов грамположительными бактериями, содержащий невпитывающую подложку, пригодную для введения во влагалище, невпитывающая подложка содержит нанесенное на нее эффективное количество соединения-предшественника, обладающего общей формулой в которой R1 выбран из группы, включающей и R7 означает -ОСН2-; Х равно 0 или 1; R5 означает замещенное или незамещенное ароматическое кольцо или одновалентный насыщенный или ненасыщенный, замещенный или незамещенный, обладающий разветвленной или линейной цепью гидрокарбильный фрагмент, который может быть или не быть замещен гетероатомами; R6 выбран из группы, включающей аминокислоту, метиловый эфир аминокислоты и этиловый эфир аминокислоты; R2, R3 и R4 независимо выбраны из группы, включающей Н, ОН, СООН, так что при гидролизе соединение-предшественник способно образовывать активное соединение, эффективное для подавления выработки экзопротеинов грамположительными бактериями. 2. Ингибитор экзопротеина ...

ANTIMIKROBIELLES MEDIZINTECHNISCHES PRODUKT, VERFAHREN ZU SEINER HERSTELLUNG UND VERWENDUNG

Self-assembly graphene oxide-protein matrix

Wound dressing materials.

ELEMENT FOR IMPLANTATION IN BODY TISSUE PARTICULARLY BONE TISSUE

FEDERATION AND PROCEDURE FOR ITS PRODUCTION.

TRI CALCIUM PHOSPHATE FOR IMPLANTATION MATERIALS.

ANTIMICROBIAL MEDICINE-TECHNICAL PRODUCT, PROCEDURE FOR ITS PRODUCTION AND USE

DECREASE OF POST OFFICE-OPERATIONAL ADHESION FORMATION WITH INTRAPERITONEAL GLUTAMIN

ELEMENT ZUR IMPLANTATION IN KNOCHENGEWEBE

Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same

A medical device including an array of microneedles and a coating disposed on or within the microneedles and a method of making such a device are disclosed. The coating includes a peptide therapeutic agent and an amino acid. A method of stabilizing a peptide therapeutic agent with an amino acid on an array of microneedles is also disclosed. In some cases, the peptide therapeutic agent and the amino acid either both have a net positive charge or both have a net negative charge. In some cases, the peptide therapeutic agent is histidine.

IRRIGATION AND STARCH HYDROLYSATE WOUND DRESSING

BIO-COMPATIBLE AND BLOOD COMPATIBLE MATERIALS AND METHODS

TRICALCIUM PHOSPHATE FOR IMPLANT MATERIALS

An absorbable porous tricalcium phosphate, in which the pores are sealed with a mixture of an antibiotic and another filler, in particular an amino acid, is particularly advantageous for use in the preparation of bone cements.

WOUND HEALING POLYMERIC NETWORKS

A composition includes at least one biologically active agent covalently attached to a first polymerizing molecule that is adapted to undergo a free radical polymerization. The first polymerizing molecule retains the ability to undergo free radical polymerization after attachment of the bioactive agent thereto. The first polymerizing molecule is preferably biocompatible. The polymerizing molecule can, for example, be dihydroxyphenyl-L-alanine (DOPA) or tyrosine. The composition can also include a second component synthesized by reacting at least one core molecule having a plurality of reactive hydrogen groups with at least one multi-isocyanate functional molecule to create a conjugate including terminal isocyanate groups. The conjugate molecule is reacted with a second polymerizing molecule that is adapted to undergo a free radical polymerization. The second polymerizing molecule includes a reactive hydrogen to react with the isocyanate groups of the conjugate. The second polymerizing molecule retains the ability to undergo the free radical polymerization after reaction with the conjugate. In several embodiments, the first polymerizing molecule and the second polymerizing molecule are the same and dihydroxyphenyl-L-alanine (DOPA) or tyrosine.

THERMORESPONSIVE COMPOSITIONS AND METHODS FOR PREVENTING AND DISRUPTING BIOFILMS

One aspect of the present disclosure can include a thermoresponsive nanocomposite for disrupting or preventing biofilm formation. The nanocomposite can include at least one polymer, one or more D-amino acids, and one or more energy-actuatable particles. The nanocomposite can have a first viscosity at about room temperature and, when exposed to about physiological temperature, obtains a second viscosity that is greater than the first viscosity. Application of energy to the nanocomposite from an energy source can excite the one or more energy-actuatable particles to cause localized heat release from the nanocomposite.

ELEMENT TO BE ESTABLISHED IN FABRIC Of a BODY, IN PARTICULAR OF BONE TISSUE

MICRONEEDLE DEVICE INCLUDING A PEPTIDE THERAPEUTIC AGENT AND AN AMINO ACID AND METHODS OF MAKING AND USING THE SAME

TECIDO HIGIÊNICO COMPREENDENDO UMA COMPOSIÇÃO INIBIDORA DE MICRÓBIO

WOUND COVERING AND PREPARATION METHOD THEREOF

The present invention relates to a wound covering with prominent biocompatible and accelerated wound-healing and its preparation method thereof. The wound covering comprises a film prepared from collagen and Dopa-containing protein—mussel adhesive protein, which is immobilized on collagen by chemical cross-linking, thus enhances the stability of protein structure and maintains the activity of collagen and mussel adhesive protein. The wound covering has excellent mechanical strength and can be trimmed into any shape; it accelerates tissue epithelisation and promotes wound healing with good biocompatibility, non-adhesive to the wound and no further wound damages. 1. A wound covering comprising a film , wherein the film is prepared from a biocompatible and high-mechanical-strength carrier and a Dopa-containing protein , wherein the carrier is collagen , and the Dopa-containing protein is mussel adhesive protein.2. The wound covering according to claim 1 , wherein the mass ratio of collagen to mussel adhesive protein is 3:1˜20:1.3. The wound covering according to claim 2 , wherein the film is made of collagen and mussel adhesive protein through chemical cross-linking.4. The wound covering according to claim 3 , wherein the dry weight of the unit area of the film is 1-5 mg/cm.5. The wound covering according to claim 4 , wherein the wound covering further comprises a preservation solution claim 4 , the preservation solution is a mixed solution containing glycerol and sodium hydrogen phosphate.6. The preparation method of the wound covering according to claim 1 , comprising the following steps: (i) dissolving mussel adhesive protein in a glacial acetic acid solution, configuring a mussel adhesive protein preservation solution with a concentration of 0.4%;', '(ii) taking 1/20-¼ of the mussel adhesive protein preservation solution of the step (i), and adding collagen to dissolve to obtain a mixed solution;', '(iii) transferring the mixed solution of step (ii) into a ...

ОСТЕОГЕННЫЙ БИОРЕЗОРБИРУЕМЫЙ МАТЕРИАЛ ДЛЯ ЗАМЕЩЕНИЯ КОСТНЫХ ДЕФЕКТОВ И СПОСОБ ЕГО ПОЛУЧЕНИЯ

FIELD: medicine. SUBSTANCE: invention refers to medicine, more specifically to injectable bioresorbable compositions of biocomposite materials for treating human bone diseases and disorders as: a material able to be biodegradable in the body completely and to be replaced by new bone tissue for the purpose of bone cell regeneration, osteoconductive and osteoinductive biological support frame for bone tissue regeneration, applied in traumatology, orthopaedics, maxillofacial surgery, and neurosurgery. The injectable biocomposite material contains biological hydroxyapatite, calcium hydrophosphate, amino acid arginine, as well as phosphoprotein (casein) recovered from skim milk, and glutaric aldehyde as a hardener. EFFECT: preparing the bioresorbable material having the biocompatibility and the pronounced osteoconductive and osteoinductive properties. 2 cl, 1 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) 2 504 405 (13) C1 (51) МПК A61L A61K A61K A61P 27/12 31/198 38/16 41/00 (2006.01) (2006.01) (2006.01) (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (21)(22) Заявка: 2012143349/15, 10.10.2012 (24) Дата начала отсчета срока действия патента: 10.10.2012 (73) Патентообладатель(и): Общество с ограниченной ответственностью "СТАЛВЕК" (RU) R U Приоритет(ы): (22) Дата подачи заявки: 10.10.2012 (72) Автор(ы): Полежаева Любовь Константиновна (RU) (45) Опубликовано: 20.01.2014 Бюл. № 2 Адрес для переписки: 115114, Москва, Шлюзовая набережная, 6, стр.4-5, ООО "Патент-Гарант", Н.О. Гершановой челюстно-лицевой хирургии, нейрохирургии. Инъекционный биокомпозиционный материал содержит биологический гидроксиапатит, гидрофосфат кальция, аминокислоту-аргинин, а также фосфопротеин (казеин), выделенный из обезжиренного молока, а в качестве отвердителя глутаровый альдегид. Технический результат заключается в получении биорезорбируемого материала, обладающего биосовместимостью и выраженными остеокондуктивными и остеоиндуктивными свойствами. 2 н.п. ф- ...

Material for a bionic cornea

The material for a bionic cornea comprises starting materials known per se on whose surface various biologically active carbohydrate group chains and/or proteins which promote corneal endothelial cell adhesion and cellular proliferation are covalently bonded or adsorbed. It is sutured in after performing a keratotomy which leaves a peripheral ring of corneal endothelial cells and, by reason of the carbohydrate group chains and/or proteins present on the surface, permits adherent and proliferative growth, which then covers the surface of the material, of the remaining corneal endothelial cells.

Prebiotic compositions and methods for maintaining a healthy skin microbiota

A composition for providing or maintaining a healthy skin microbiota and methods of providing or maintaining a healthy skin microbiota are disclosed. The composition can be a prebiotic composition that can include a carrier and a skin microbiota balancing agent. In some aspects, the skin microbiota balancing agent can include at least one combination of carbohydrate sources including a first carbohydrate source and a second carbohydrate source. The skin microbiota balancing agent can be configured to provide at least two of the following desired ratios: a first desired ratio of Corynebaderium to Staphylococcus of 1.3, a second desired ratio of Corynebaderium to Micrococcus of 1.4, and a third desired ratio of Staphylococcus to Micrococcus of 1.1. The carbohydrate sources may be D-alanine, D-threonine, L-alanyl-glycine, succinic acid, a-keto-glutaric acid, m-tantaric acid, bromo succinic acid, mucic acid, phenylethyl-amine, inulin, oxalic acid, pectin, Tween 40 etc.

IMPLANT

Coated implant

Coated implant of metals, metal alloys, synthetic plastics material, ceramics and/or other substances, characterised in that an implant is provided with a coating system which consists of a passivating coating and/or several physiologically active coatings, or is provided with a passivating, physiologically active coating, the physiologically active coatings being composed of organic constituents of identical nature.

PROCEDURE FOR THE PRODUCTION OF WUNDHEILUNGSFOERDERNDER PREPARATIONS AND SUCH PREPARATIONS.

ELEMENT ZUR IMPLANTATION IN KNOCHENGEWEBE

PHARMACEUTICAL WUNDHEILUNGS COMPOSITIONS IN FORM OF A STERILE POWDER ON BASIS OF AMINO ACIDS AND NATRIUMHYALURONAT

Reducing post-operative adhesion formation with intraperitoneal glutamine

System and method for the prevention of bacterial and fungal infections including urinary tract infections (UTI) using N-halogenated amino acids

Polypeptide and hyaluronic acid coatings

The present invention concerns a polyelectrolyte coating comprising at least one polycationic layer consisting of at least one polycation consisting of n repetitive units having the formula (1) and at least one polyanionic layer consisting of hyaluronic acid. The polyelectrolyte coating has a biocidal activity and the invention thus further refers to the use of said polyelectrolyte coating for producing a device, in particular a bacteriostatic medical device, more particularly an implantable device, comprising said polyelectrolyte coating, and a method for preparing said device and a kit.

Medium and matrix for long-term proliferation of cells

REDUCING POST-OPERATIVE ADHESION FORMATION WITH INTRAPERITONEAL GLUTAMINE

Intraperitoneal administration of glutamine reduces post-operative adhesion formation.

ACTIVATED POLYMERS BINDING BIOLOGICAL MOLECULES

The present invention relates to activated polymer substrates capable of binding functional biological molecules, to polymer substrates comprising bound and functional biological molecules, to devices comprising such substrates and to methods of producing them.

ANTIMICROBIAL COMPOSITIONS AND METHODS FOR LOCKING CATHETERS

Antimicrobial compositions for use in locking catheters and other devices are provided. In some embodiments, the composition includes at least one alcohol, at least one biocidal agent which is not an alcohol, and one or more poloxamers; in other embodiments, the composition comprises at least one poloxamer and at least one alcohol. The composition can provide long-lasting antimicrobial activity. Methods of using the composition are also provided.

MICRONEEDLE DEVICE HAVING A PEPTIDE THERAPEUTIC AGENT AND AN AMINO ACID, METHODS OF MAKING AND USING THE SAME

A medical device including an array of microneedles and a coating disposed on or within the microneedles and a method of making such a device are disclosed. The coating includes a peptide therapeutic agent and an amino acid. A method of stabilizing a peptide therapeutic agent with an amino acid on an array of microneedles is also disclosed. In some cases, the peptide therapeutic agent and the amino acid either both have a net positive charge or both have a net negative charge. In some cases, the peptide therapeutic agent is histidine.

MATTRESS FOR PREVENTION AND TREATMENT OF DECUBITUS ULCERS

La présente invention concerne un matelas pour la prévention et le traitement des escarres comportant un corps principal (1) et un élément échangeable (2, 3, 4), ledit élément échangeable (2, 3, 4) comportant une composition absorbante (7) et une composition désinfectante (8). La présente invention concerne encore un procédé de fabrication d'un tel matelas, et comportant les étapes suivantes : - réalisation du corps principal (1), revêtu d'une housse (5), en particulier en jersey plastifié, avec un logement pour un élément échangeable (2, 3, 4), - réalisation d'un élément échangeable (2, 3, 4) en carton alvéolé nids d'abeilles ou en mousse alvéolée viscoélastique, - dépôt d'une composition absorbante (7) dans l'élément échangeable, - dépôt d'une composition désinfectante (8) sur la composition absorbante, - disposition d'une enveloppe (11) autour de l'élément échangeable (2, 3, 4), constituée en particulier d'un textile non-tissé perméable, - placement de l'élément échangeable (2, 3, 4) ...

WOUND DRESSING MATERIALS

A wound dressing material comprising: a wound dressing carrier, N-acetyl cysteine or a salt or derivative thereof, and a stabilized ascorbate. Suitably, the stabilized ascorbate comprises an ascorbate-2-polyphosphate. Also provided are wound dressing comprising the materials, methods of treatment with the materials, and methods of making the materials.

WOUND HEALING POLYMERIC NETWORKS

A composition includes at least one biologically active agent covalently attached to a first polymerizing molecule that is adapted to undergo a free radical polymerization. The first polymerizing molecule retains the ability to undergo free radical polymerization after attachment of the bioactive agent thereto. The first polymerizing molecule is preferably biocompatible. The polymerizing molecule can, for example, be dihydroxyphenyl-L-alanine (DOPA) or tyrosine. The composition can also include a second component synthesized by reacting at least one core molecule having a plurality of reactive hydrogen groups with at least one multi-isocyanate functional molecule to create a conjugate including terminal isocyanate groups. The conjugate molecule is reacted with a second polymerizing molecule that is adapted to undergo a free radical polymerization. The second polymerizing molecule includes a reactive hydrogen to react with the isocyanate groups of the conjugate. The second polymerizing molecule ...

ANTIMICROBIAL MEDICAL PRODUCT, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF

The invention relates to a medical product with an anti-microbial coating made from a complex material of metal nanoparticles and macromolecules, the macromolecules being at least partly formed from a polyamino acid.

MATTRESS FOR PREVENTING AND TREATING BEDSORES

The present invention relates to a mattress for preventing and treating bedsores comprising a main body (1) and an exchangeable element (2, 3, 4), said exchangeable element (2, 3, 4) comprising an absorbent composition (7) and a disinfectant composition (8). The present invention also relates to a method for manufacturing such a mattress, and comprising the following steps: production of the main body (1), covered with a cover (5), in particular in plasticized jersey, with a housing for at least one exchangeable element (2, 3, 4), production of an exchangeable element (2, 3, 4) in honeycomb cardboard or viscoelastic cellular foam, deposition of an absorbent composition (7) in the exchangeable element, deposition of a disinfectant composition (8) on the absorbent composition, arrangement of an envelope (11) around the exchangeable element (2, 3,4), made in particular of a permeable nonwoven textile, placement of the exchangeable element (2, 3, 4) in the car responding housing of the main ...

REDUCING POST-OPERATIVE ADHESION FORMATION WITH INTRAPERITONEAL GLUTAMINE

Intraperitoneal administration of glutamine to reduce adhesions in the peritoneum of a patient. 118-. (canceled)19. A method of treating or reducing adhesions in the peritoneum of a patient in need thereof , comprising:(a) performing adhesiolysis on one or more adhesions involving the patient's peritoneum and/or one or more tissues or organs in the patient's peritoneal cavity; and(b) administering to the peritoneum or the peritoneal cavity of the patient an effective amount of a composition comprising at least one glutamine source;wherein the glutamine source is selected from one or more of L-glutamine, physiologically acceptable salts of L-glutamine, and dipeptides comprising L-glutamine.20. The method of claim 19 , wherein the glutamine source is L-glutamine or a physiologically acceptable salt thereof.21. The method of claim 19 , wherein the dipeptide is selected from alanyl-glutamine and glycyl-glutamine.22. The method of claim 21 , wherein the dipeptide is alanyl-glutamine.23. The method of claim 21 , wherein the glutamine residue of the dipeptide is at the C-terminus of the dipeptide.24. The method of claim 23 , wherein the glutamine residue is L-glutamine.25. The method of claim 19 , wherein the composition is selected from the group consisting of a liquid composition claim 19 , a paste composition claim 19 , and a gel composition.26. The method of claim 25 , wherein the liquid composition is a sterile aqueous composition.27. The method of claim 19 , wherein the composition is impregnated in a surgical material.28. The method of claim 27 , wherein the surgical material is a mesh.29. The method of claim 25 , wherein the gel composition is a hydrogel. This application is a Continuation application of U.S. patent application Ser. No. 15/480,148, filed Apr. 5, 2017; which is a Continuation application of U.S. patent application Ser. No. 14/660,382, filed Mar. 17, 2015, now abandoned; which is a Continuation application of U.S. patent application Ser. No. 13/779, ...

КОМПОЗИЦИОННАЯ КОЛЛАГЕНОВАЯ ГУБКА И СПОСОБ ЕЕ ИЗГОТОВЛЕНИЯ

... 1. Композиционная коллагеновая губка, содержащая коллаген и факторы роста клеток, где композиционная коллагеновая губка имеет водопоглощающую способность более чем 52 раза.2. Композиционная коллагеновая губка по п. 1, имеющая модуль упругости более чем 70,0 Н/см.3. Композиционная коллагеновая губка по п. 2, дополнительно содержащая защитный агент в количестве 10%-50% по массе относительно массы композиционной коллагеновой губки, где указанный защитный агент содержит аминокислоты, сахариды и альбумин в массовом отношении от 1 до 11: от 1,25 до 17,5: от 1 до 7,5, где аминокислоты представляют собой по меньшей мере одну аминокислоту, выбранную из лейцина, изолейцина, глицина, аланина и серина; и сахариды представляют собой по меньшей мере один сахарид, выбранный из глюкозы, лактозы, сахарозы, трегалозы и маннита.4. Композиционная коллагеновая губка по п. 3, где защитный агент добавлен таким образом, что конечная концентрация аминокислот, добавленных в раствор коллагена, составляет 2,0-22 мг ...

Wound dressing materials

Bio-compatible and blood compatible materials and methods

Bio- and blood compatible materials are prepared by treating the surface of a substrate to provide reactive primary or secondary amine groups sites which are activated by treatment with a dialdehyde or acrylchloride for coupling to a biological compound in an amount sufficient to provide compatibility. The use of specific substrates, such as a compliant and elastic material, such as a fabric-elastomer membrane matrix, results in a product having advantageous qualities as a thermal burn dressing.

Antiseptic compositions, methods and systems

PHARMACEUTICAL COMPOSITIONS USING AMINO ACIDS FOR PROMOTING HEALING OF WOUNDS

Wound dressing materials

A wound dressing material comprising: a wound dressing carrier, N-acetyl cysteine or a salt or derivative thereof, and a stabilized ascorbate. Suitably, the stabilized ascorbate comprises an ascorbate-2-polyphosphate. Also provided are wound dressing comprising the materials, methods of treatment with the materials, and methods of making the materials.

METHOD AND COMPOSITION FOR TREATMENT OF WOUNDS

METHOD AND COMPOSITION FOR TREATMENT OF WOUNDS Treatment of skin wounds with starch hydrolysate composition can be improved by irrigating the wound with a buffered salt solution having a pH in the range of approximately 6-7.8 prior to application of the starch hydrolysate composition. Additionally, the treatment can include further irrigation with amino acid solution. A preferred starch hydrolysate composition is compounded to include alphaketoglutaric acid . or a salt thereof.

ELEMENT FOR IMPLANTATION IN BODY TISSUE PARTICULARLY BONE TISSUE

Wound dressing materials

A wound dressing material comprising: a wound dressing carrier, N-acetyl cysteine or a salt or derivative thereof, and a stabilized ascorbate. Suitably, the stabilized ascorbate comprises an ascorbate-2-polyphosphate. Also provided are wound dressing comprising the materials, methods of treatment with the materials, and methods of making the materials.

Antimicrobial disposable absorbent articles

Disposable absorbent articles comprising an absorbent material and an antimicrobial composition are disclosed. The antimicrobial composition includes a carrier comprising fatty alcohol and a poly(alkyleneoxy) polymer, and an antimicrobial agent. The antimicrobial composition may be coated on to component substrates such as nonwovens and films, that are incorporated into disposable absorbent articles, such as disposable infant diapers, adult incontinence articles, feminine hygiene articles such as sanitary napkins, wound dressings, bandages, panty liners and tampons, personal care wipes and household wipes to provide odor control, and control of microbial growth.

DRUG DELIVERY COMPOSITIONS AND METHODS

A drug delivery composition is disclosed which includes a triple salt proxy functional group and at least one amino acid functional group. A method of forming the drug delivery composition includes reacting a triple salt with at least one amino acid in an aqueous environment. A biodegradable fabric is disclosed which includes a polymerized structure of a triple salt proxy functional group and at least one amino acid functional group. 1. A drug delivery composition comprising a triple salt proxy functional group and at least one amino acid functional group , wherein the triple salt proxy functional group includes a peroxy moiety.2. The drug delivery composition of claim 1 , wherein the triple salt proxy functional group is KHSO.3. The drug delivery composition of claim 1 , wherein the amino acid functional group is selected from the group consisting of derivatives of glutamine claim 1 , alanine claim 1 , aspartic acid claim 1 , lysine claim 1 , glycine claim 1 , cysteine claim 1 , arginine claim 1 , proline claim 1 , naturally occurring peptides claim 1 , artificially occurring peptides claim 1 , and combinations thereof.4. The drug delivery composition of claim 1 , wherein the triple salt proxy functional group includes the property of broad spectrum antimicrobial activities against bacteria claim 1 , fungi and viruses.5. The drug delivery composition of claim 1 , wherein the drug delivery composition further comprises a plurality of amino acid functional groups.6. The drug delivery composition of claim 5 , wherein the plurality of amino acid functional groups further comprises amino acid health benefits.7. The drug delivery composition of claim 1 , wherein the drug delivery composition is a powder base material.8. The drug delivery composition of claim 7 , wherein the powder base material further comprises the property of rapid solubility in an aqueous solution.9. A method for forming a drug delivery composition comprising reacting a triple salt including a peroxy ...

Antimicrobial disposable absorbent articles

Disposable absorbent articles comprising an absorbent material and an antimicrobial composition are disclosed. The antimicrobial composition includes a carrier comprising fatty alcohol and a poly(alkyleneoxy) polymer, and an antimicrobial agent. The antimicrobial composition may be coated on to component substrates such as nonwovens and films, that are incorporated into disposable absorbent articles, such as disposable infant diapers, adult incontinence articles, feminine hygiene articles such as sanitary napkins, wound dressings, bandages, panty liners and tampons, personal care wipes and household wipes to provide odor control, and control of microbial growth.

Antimicrobial Compositions and Methods for Locking Catheters

Antimicrobial compositions for use in locking catheters and other devices are provided. In some embodiments, the composition includes at least one alcohol, at least one biocidal agent which is not an alcohol, and one or more poloxamers; in other embodiments, the composition comprises at least one poloxamer and at least one alcohol. The composition can provide long-lasting antimicrobial activity. Methods of using the composition are also provided.

FLOWABLE TISSUE COMPOSITIONS WITH ENHANCED BUOYANCY PROPERTIES CONTAINING ANTIBIOTICS AND DERIVATIVES THEREOF

Disclosed are compositions of matter, protocols, and treatment means for generation of tissues capable of administration in a flowable manner through contain with one or more antibiotics, or derivatives of said antibiotics. In one embodiment the invention provides the treatment of morselized amniotic membranes with antibiotics in a manner as to increase buoyancy of morselized components of said amniotic membranes in order to prevent gravity based accumulation of said morselized tissue. In another embodiment buoyancy of morselized tissue is modulated by contacting said tissue with an antibiotic or derivative thereof in a manner to allow for increased uniformity of said morselized tissue components throughout a vessel. In another embodiment, pancreatic islets are isolated and stored in a manner to prevent gravity based aggregation. The invention pertains to all tissues, with emphasize in a preferred embodiment to tissues which are useful when administered in a flowable manner. 1. A method for modulating buoyancy of a dissected tissue in which said dissected tissue is contacted with an agent selected from the group consisting of: an antibiotic , a plurality of antibiotics , and a derivative of an antibiotic , at a sufficient concentration and timepoint to achieve a desired buoyancy.2. The method of claim 1 , wherein said dissection comprises morselization of said tissue.3. The method of claim 1 , wherein said dissection comprises cutting of said tissue.4. The method of claim 1 , wherein said dissection comprises grinding of said tissue.5. The method of claim 1 , wherein said dissection comprises shearing of said tissue.6. The method of claim 1 , wherein said dissection comprises sonication of said tissue.7. The method of claim 1 , wherein said dissection comprises application of mechanical pressure of sufficient strength in order to cause dissociation of said tissue into parts smaller than the original tissue.8. The method of claim 1 , wherein said buoyancy is ...

BIOLOGIC COMPOSITION AND METHOD OF USE

A biologic composition responsive to inflammation has an allograft scaffold matrix for injection or implantation. The allograft scaffold matrix has donor quiescent and/or senescent cells. The donor quiescent and/or senescent cells react in response to signaling of inflammation from host cells or matrix. The reaction to signaling causes the donor quiescent and/or senescent cells to secrete anti-inflammatory cytokines and secrete exosomes to initiate regeneration of the area of the inflammation. The biologic composition further has a cryoprotectant. The cryoprotectant is a polyampholyte, preferably the polyampholyte is an ε-poly-L-lysine. The cryoprotectant is not DMSO or glycerol based. The cryoprotectant is suitable for direct implantation without washing from the allograft scaffold matrix in either a diluted or non-diluted state. 1. A biologic composition responsive to inflammation , the biologic composition comprises:an allograft scaffold matrix for injection or implantation having donor senescent cells, wherein the donor senescent cells react in response to signaling of inflammation from host cells, wherein the reaction to signaling causes the donor senescent cells to secrete anti-inflammatory cytokines.2. The biologic composition of further comprises:a cryoprotectant.3. The biologic composition of wherein the cryoprotectant is a polyampholyte.4. The biologic composition of is not DMSO or glycerol based.5. The biologic composition of wherein the cryoprotectant is suitable for direct implantation without washing from the allograft scaffold matrix in either a diluted or non-diluted state.6. The biologic composition of wherein the polyampholyte is an ε-poly-L-lysine.7. The biologic composition of wherein the donor senescent cells are derived from bone marrow.8. The biologic composition of wherein the donor senescent cells are derived from placental tissue.9. The biologic composition of wherein the allograft scaffold matrix further comprises allograft bone in the ...

REDUCING POST-OPERATIVE ADHESION FORMATION WITH INTRAPERITONEAL GLUTAMINE

Intraperitoneal administration of glutamine to reduce adhesions in the peritoneum of a patient. 1. A composition for intraperitoneal administration comprising a pharmaceutically acceptable carrier and at least one glutamine source.2. The composition of claim 1 , wherein the at least one glutamine source is a soluble peptide containing L-glutamine.3. The composition of claim 2 , wherein the soluble peptide is a dipeptide.4. The composition of claim 3 , wherein the dipeptide is alanylglutamine.5. The composition of claim 1 , wherein the at least one glutamine source is L-glutamine.6. The composition of wherein the composition is formulated as a gel.7. The composition of claim 1 , wherein the composition is impregnated in a surgical material.8. The composition of claim 7 , wherein the surgical material is a mesh.9. A medical device comprising the composition of .10. A delivery device containing the composition of claim 1 , wherein the device is for delivery of the composition intraperitoneally during surgery.11. A method of treating a patient to reduce post-operative adhesion formation comprising intraperitoneal administration of an effective amount of a glutamine source to said patient.12. The method of claim 11 , wherein the glutamine source comprises L-glutamine amino acid.13. The method of claim 11 , wherein the glutamine source comprises a soluble peptide containing L-glutamine.14. The method of claim 13 , wherein the peptide is a dipeptide.15. The method of claim 14 , wherein the dipeptide is alanyl-glutamine.16. The method of claim 11 , wherein the glutamine source is delivered to the peritoneal cavity during surgery.17. The method of claim 11 , wherein the glutamine source is in a gel formulation.18. The method of claim 11 , wherein the glutamine source is placed on or is impregnated in a surgical material or an implantable medical device. This application is a Continuation application of U.S. patent application Ser. No. 14/660,382, filed Mar. 17, 2015; which ...

Antimicrobial Compositions and Methods for Locking Catheters

Antimicrobial compositions for use in locking catheters and other devices are provided. In some embodiments, the composition includes at least one alcohol, at least one biocidal agent which is not an alcohol, and one or more poloxamers; in other embodiments, the composition comprises at least one poloxamer and at least one alcohol. The composition can provide long-lasting antimicrobial activity. Methods of using the composition are also provided. 1. A catheter containing a locking solution comprising an antimicrobial composition , the antimicrobial composition comprising:at least one poloxamer;at least 10 weight percent of at least one alcohol on a basis of total weight of the antimicrobial composition; andat least one biocidal agent that is not an alcohol.3. The catheter of claim 2 , wherein the average molecular weight of the poloxamer is between about 2 claim 2 ,000 to about 18 claim 2 ,000 daltons.4. The catheter of claim 3 , wherein the at least one poloxamer is selected from the group consisting of poloxamer 188 claim 3 , poloxamer 237 and poloxamer 407.5. The catheter of claim 1 , wherein the poloxamer is present in an amount of about 0.01 wt. % to about 5 wt. % claim 1 , based on the weight of the antimicrobial composition.6. The catheter of claim 1 , wherein the at least one biocidal agent that is not an alcohol is selected from the group consisting of β-propiolactone claim 1 , α-terpineol claim 1 , 1-(3-choroallyl)-3 claim 1 ,5 claim 1 ,7-triazo-1-azoniaadamantane chloride claim 1 , 1 claim 1 ,4-dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid claim 1 , 1-cyclopropyl-6-fluoro-1 claim 1 ,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid claim 1 , 1-napthyl salicylate claim 1 , 2-(methoxymethyl)-5-nitrofuran claim 1 , 2 claim 1 ,4 claim 1 ,4′-trichloro-2′-hydroxydiphenol claim 1 , 2 claim 1 ,4 claim 1 ,6-tribromo-m-cresol claim 1 , 2-bromo-2-nitropropan-1 claim 1 ,3-diol claim 1 , 2-napthyl salicylate claim 1 , 3 claim 1 ...

ANTIMICROBIAL COMPOSITIONS

An anti-microbial composition, comprising a chelator (such as EDTA and its salts), and a transport enhancer (such as Methyl Sufonyl Methane; MSM) is provided. Together, the combination of the two substances unexpectedly and beneficially inhibits bacterial or fungal biofilms when administered to an area of microbial infection. Preferred formulations include spray, lotion, solution, gel, cream, ointment, soap, deodorant, surgical rinse, or dental rinse. 1. An antimicrobial formulation , comprising:a chelating agent or salts thereof;a transport enhancer; andan acceptable vehicle or base for such composition;wherein the chelating agent and the transport enhancer are present in a proportion effective to bring about a significant reduction in bacterial and/or fungal biofilm on a surface to which it is applied, andwherein the percentage of chelator is about 0.1% to 15% and the percentage of transport in the composition is about 0.1% to 40% by weight, respectively.2. The formulation of claim 1 , wherein the transport enhancer is MSM.3. The formulation of claim 1 , wherein the transport enhancer is DMSO.4. The formulation of claim 2 , wherein the proportion of the chelator to MSM is in the range of about 10:1-1:20.5. The formulation of claim 1 , wherein the composition comprises a formulation selected from solid claim 1 , liquid claim 1 , inhalant claim 1 , spray claim 1 , lotion claim 1 , solution claim 1 , gel claim 1 , cream claim 1 , ointment claim 1 , surgical rinse claim 1 , or dental rinse.6. The formulation of claim 1 , wherein the chelating agent is selected from ethylenediamine tetraacetic acid (EDTA) claim 1 , ethylene glycol tetraacetic acid (EGTA) claim 1 , cyclohexanediamine tetraacetic acid (CDTA) claim 1 , hydroxyethylethylenediamine triacetic acid (HEDTA) claim 1 , diethylenetriamine pentaacetic acid (DTPA) claim 1 , dimercaptopropane sulfonic acid (DMPS) claim 1 , dimercaptosuccinic acid (DMSA) claim 1 , aminotrimethylene phosphonic acid (ArPA) claim 1 , ...

SYRINGE TREATED WITH TRANSDERMAL VENOUS ACCESS LOCKING SOLUTIONS AND METHOD OF TREATING THE SYRINGE

Microbial growth inhibiting solutions and methods of employing the microbial growth inhibiting solutions in flushing and coating medical devices are disclosed. In alternative embodiments, the microbial growth inhibiting solutions include combinations of a chelating agent with a C-Ccarboxylate antimicrobial agent, for example, such as n-capric, n-lauric, or n-octanoic acid. Methods of using these microbial growth inhibiting solutions for coating a medical device and for inhibiting catheter infection are also disclosed. Methods of using these microbial growth inhibiting solutions, or portions thereof, as leaching treatment solutions to treat polymer syringes and the treated syringes are also disclosed. 1. An apparatus , the apparatus comprising:a syringe having polymer components, the polymer components treated with a leaching treatment solution.2. The apparatus of wherein the leaching treatment solution includes a C-Ccarboxylate.3. The apparatus of wherein the wherein the C-Ccarboxylate is selected from the group consisting of:{'sub': 3', '11, 'agents having the formula R—COOH wherein R=C-Cn-alkyl, pharmaceutically acceptable salts thereof and combinations thereof.'}4. The apparatus of wherein the C-Ccarboxylate is selected from the group consisting of n-butyric acid claim 2 , n-pentanoic acid claim 2 , n-hexanoic acid claim 2 , n-heptanoic acid claim 2 , n-octanoic acid claim 2 , n-nonanoic acid claim 2 , n-capric acid claim 2 , and n-lauric acid claim 2 , pharmaceutically acceptable salts thereof and combinations thereof.5. The apparatus of wherein the leaching treatment solution further comprises a chelating agent claim 2 , wherein the chelating agent is present in an amount ranging from about 0.01 mg/mL to about 2 mg/mL.6. The apparatus of claim 2 , wherein the C-Ccarboxylate is present in an amount ranging from about 0.05 mg/mL to about 5 mg/mL.7. The apparatus of claim 5 , wherein the chelating agent is selected from the group consisting of ...

BIOARTIFICIAL MEMBRANES HAVING CONTROLLED VISCOELASTICITY AND RIGIDITY FOR USE IN TISSUE ENGINEERING

The present invention belongs to the field of biomedicine and tissue engineering. Specifically, it relates to a biomaterial and to an in vitro method for preparing a tissue or bioartificial membrane having controlled elasticity and rigidity, and to the tissue or artificial membrane obtainable using the method. The invention further relates to the uses thereof in medicine. 21. The biomaterial according to claim , where Ris —OR3. The biomaterial according to claim 1 , wherein Ris —H or Calkyl4. The biomaterial according to claim 1 , wherein Ris H or Calkyl or Ris —CH—OH claim 1 , —CH—CH—OH claim 1 , or —CH—CH—CH—OH.5. The biomaterial according to claim 1 , wherein Ris H or Calkyl.6. The biomaterial according to claim 1 , wherein Ris —CH—OH claim 1 , —CH—CH—OH claim 1 , —CH—CH—CH—OH.8. The biomaterial according to claim 1 , wherein the origin of the fibrinogen or fibrin is blood plasma.9. The biomaterial according to claim 8 , wherein the blood plasma is of autologous origin.10. The biomaterial according to claim 1 , wherein the antifibrinolytic agent is tranexamic acid.11. The biomaterial according to claim 1 , wherein the source of calcium is a calcium salt.12. The biomaterial according to claim 11 , wherein the calcium salt is calcium chloride.13. The biomaterial according to claim 1 , wherein the polysaccharide is agarose.14. The biomaterial according to claim 13 , wherein the agarose is type VII agarose.15. The biomaterial according to claim 1 , further comprising a protein.16. The biomaterial according to claim 15 , wherein the protein is selected from fibronectin claim 15 , collagen claim 15 , or the combination thereof.17. The biomaterial according to claim 15 , wherein the protein is type I collagen.18. (canceled)19. An artificial tissue comprising the biomaterial according to claim 1 , and further comprising mammalian cells.2034-. (canceled)35. A method for increasing claim 19 , restoring claim 19 , or partially or completely substituting the functional ...

SUTURE ANCHOR WITH SOFT ANCHOR OF ELECTROSPUN FIBERS

A flexible anchor for coupling a suture to a bone is provided. The anchor is composed of non-woven electrospun fibers and has an elongate tubular body that extends from a first end to a second end. The anchor is configured to receive a suture that enters the anchor through a first aperture and exits the anchor through a second aperture. When free ends of the suture are pulled, the anchor transitions from a first configuration to a second anchoring configuration. 1. An anchor for coupling a suture to a bone , the anchor comprising an elongate tubular body extending from a first end to a second end in , the anchor being configured to receive a suture that enters the anchor through a first aperture and exits the anchor through a second aperture , wherein pulling free ends of the suture sets the anchor in an anchoring configuration when the anchor is inserted in a bore in a bone , wherein the anchor comprises a non-woven material.2. The anchor according to claim 1 , wherein the non-woven material comprises electrospun fibers with a diameter of from about 1 nm to about 50 μm.3. The anchor according to claim 2 , wherein the electrospun fibers have a diameter that is near the size of collagen fibrils or collagen fiber bundles.4. The anchor according to claim 3 , wherein the fibers have a diameter of from about 0.1 μm to about 10 μm.5. The anchor according to claim 2 , wherein the electrospun fibers include at least one of a modifying agent for promoting cellular attachment; a biological agent for stimulating cell infiltration claim 2 , promoting differentiation and maturation of repair tissue claim 2 , or decreasing inflammation; or an antimicrobial agent selected from the group consisting of antifungal agents claim 2 , antiviral agents claim 2 , antibacterial agents claim 2 , and combinations thereof.6. The anchor according to claim 5 , wherein the modifying agent is chitosan claim 5 , gelatin claim 5 , collagen claim 5 , silk fibroin claim 5 , polyethylene glycol claim 5 ...

Therapeutic compositions of undecylenic acid and arginine

Compositions including a complex of fatty acids (e.g., including one or more C4 to C40 fatty acids, such as a C4 to C20 fatty acid) and one or more amino acids (and particularly one or more amino acids having electrically charged basic side chains, e.g., Arginine, Lysine, etc.) for use as an anti-pathogenic composition. These compositions may include the complex of fatty acid:amino acid having a lamellar supramolecular structure. In particular, described herein are therapeutic compositions of undecylenic acid:Arginine forming a complex of undecylenic acid and Arginine.

WOUND DRESSING MATERIALS

A wound dressing material comprising: a wound dressing carrier, N-acetyl cysteine or a salt or derivative thereof, and a stabilized ascorbate. Suitably, the stabilized ascorbate comprises an ascorbate-2-polyphosphate. Also provided are wound dressings comprising the materials, methods of treatment with the materials, and methods of making the materials. 1. A wound dressing material comprising: a wound dressing carrier , N-acetyl cysteine or a salt or derivative thereof; and a stabilized ascorbate.2. A wound dressing material according to claim 1 , wherein the material comprises from about 0.1 wt. % to about 20 wt. % of said N-acetyl cysteine or salts or derivatives thereof claim 1 , and from about 0.1 wt. % to about 20 wt. % of said stabilized ascorbate.3. A wound dressing material according to claim 2 , wherein the material comprises from about 1 wt. % to about 10 wt. % of said N-acetyl cysteine or salts or derivatives thereof claim 2 , and from about 1 wt. % to about 10 wt. % of said stabilized ascorbate.4. A wound dressing material according to claim 1 , wherein the weight ratio of N-acetyl cysteine or salts or derivatives thereof claim 1 , to said stabilized ascorbate is from about 1:4 to about 4:1.5. A wound dressing material according to claim 1 , wherein said stabilized ascorbate is selected from the group consisting of ascorbate 2-phosphate or polyphosphate compounds claim 1 , Trisodium-L-ascorbyl-2-monophosphate; 2-Phospho-L-ascorbic acid trisodium salt claim 1 , Magnesium Ascorbyl Phosphate (MAP) claim 1 , L-Ascorbic acid mono(dihydrogen phosphate) magnesium salt claim 1 , Magnesium L-ascorbic acid-2-phosphate claim 1 , trisodium-L-ascorbyl-2-polyphosphate claim 1 , and mixtures thereof.6. A wound dressing material according to claim 5 , wherein said stabilized ascorbate comprises or consists essentially of an ascorbate-2-polyphosphate.7. A wound dressing material according to claim 5 , wherein the material comprises N-acetyl cysteine and ascorbate-2- ...

SELF-ASSEMBLING GRAPHENE OXIDE-PROTEIN MATRIX

The present invention relates to a stable self-assembling graphene oxide-protein matrix comprising a disordered protein (DP) and graphene oxide (GO), wherein the DP has an opposite charge to the GO, further wherein the graphene oxide-protein matrix is in the form of a 3D structure having a lumen defined by a membrane having an inner and outer surface. The invention further relates to methods and kits for preparing such a graphene oxide-protein matrix and its uses. 1. A method of preparing a graphene oxide-protein matrix , the method comprising; admixing an aqueous solution of a disordered protein (DP) with an aqueous solution of graphene oxide (GO) , wherein the DP has an opposite charge to the GO , further wherein the graphene oxide-protein matrix is in the form of a three-dimensional (3D) structure having a lumen defined by a membrane having an inner and outer surface.2. A graphene oxide-protein matrix comprising a disordered protein (DP) and graphene oxide (GO) , wherein the DP has an opposite charge to the GO , further wherein the graphene oxide-protein matrix is in the form of a 3D structure having a lumen defined by a membrane having an inner and outer surface.5. The method , graphene oxide-protein matrix , or kit of any previous claim , wherein the 3D structure isa. multilamellarb. a tube; orc. a membrane, a multi-lamella tube, a tubular network, a sphere, a cavity, a sac, or a vesicle.6. The method , graphene oxide-protein matrix , or kit of any previous claim , wherein;a. the internal diameter of the lumen of 3D structure is at least 10 μm; and/orb. the membrane of the 3D structure is from about 5 μm to about 50 μm thick.7. The method , graphene oxide-protein matrix , or kit of any previous claim , wherein the aqueous solution of DP is added to the aqueous solution of GO.8. The method , graphene oxide-protein matrix , or kit of any previous claim , wherein:a. prior to matrix assembly the DP is comprised of at least 35% random coil structure and at least 5% ...

Suture Anchor With Soft Anchor Of Electrospun Fibers

A flexible anchor for coupling a suture to a bone is provided. The anchor is composed of non-woven electrospun fibers and has an elongate tubular body that extends from a first end to a second end. The anchor is configured to receive a suture that enters the anchor through a first aperture and exits the anchor through a second aperture. When free ends of the suture are pulled, the anchor transitions from a first configuration to a second anchoring configuration

WOUND PACKING MATERIAL COMPRISING CHEMOEFFECTOR

A wound packing material, particularly suitable for use in negative pressure wound therapy, comprising a porous material admixed with a chemoattractant. This disclosure further provides methods of manufacturing the wound packing material, and therapeutic methods of using the wound packing material. 1. A wound packing material admixed or impregnated with at least one chemoeffector agent.2. The wound packing material of claim 1 , wherein the chemoeffector agent is chemoattractant to a microorganism.3. The wound packing material of claim 1 , wherein the chemoattractant agent is chemoattractant to a human cell infected with a virus.4. The wound packing material of claim 2 , wherein the chemoattractant agent is chemoattractant to a bacteria.5AcinetobacterBurkholdaria cepacia, Campylobacter jejuni, Candida albicansCandida glabrataEntamoeba histolyticaPlasmodiumEnterobacteria, EnterococcusEscherichia coli, Helicobacter pylori, Klebsiella pneumonia, Listeria monocytogenes, Mucormycosis, Mycobacterium tuberculosis, PasturellaPropionibacterium acnes, Proteus mirabilis, Pseudomonas aeruginosa, Salmonella typhi, paratyphi, Serratia marcescensSerratiaShigelladysenteriae, flexneri, boydii, sonneiStaphylococcus aureusStaphylococcus epidermidis, Staphylococcus lugdunensis, Staphylococcus saprophyticus, Streptococcus agalactiae, Streptococcus pneumonia, Streptococcus pyogenes,Vibrio. The wound packing material of claim 1 , wherein the chemoeffector agent is chemoattractant to a at least one microorganism selected from the group consisting of: spp claim 1 , (binding proteins) claim 1 , (binding proteins) claim 1 , (protozoan) claim 1 , spp (protozoan) claim 1 , (VRE) claim 1 , spp claim 1 , and other spp claim 1 , spp () claim 1 , (CA MRSA claim 1 , MRSA MSSA) biofilms claim 1 , and spp.6. The wound packing material of claim 1 , wherein the chemoeffector agent is selected from an amino acid claim 1 , a peptide claim 1 , a protein claim 1 , a sugar claim 1 , a mucin claim 1 , a human ...

Antiseptic compositions, methods and systems

Antiseptic compositions comprising at least one salt of EDTA are disclosed. These compositions have broad spectrum antimicrobial and antifungal activity and they also have anticoagulant properties. The antiseptic compositions have also demonstrated activity in penetrating and breaking down microbial slime, or biofilms. They are safe for human and medical uses and may be used as prophylactic preparations to prevent infection, or to reduce the proliferation of and/or eliminate existing or established infections. 1. A method , comprising:contacting, with a solution, one or more of a water storage system, a water distribution system, a water purification device, a humidification device and a dehumidification device,wherein the solution comprises at least one ethylene diamine tetra acidic acid (EDTA) salt and a solvent,wherein the at least one EDTA salt comprises tetra-sodium EDTA,wherein the solution is at a pH greater than 8.5 and a concentration of at least 0.5% (w/v) EDTA.2. The method of claim 1 , wherein the solution is at a concentration of at most 30% (w/v) EDTA.3. The method of claim 1 , further comprising reconstituting a powder or lyophilized form by adding a reconstituting solvent to produce the solution.4. The method of claim 1 , wherein the at least one EDTA salt further comprises tri-sodium EDTA.5. The method of claim 1 , wherein the solution further comprises between 0.5% and 40%/(v/v) ethanol and a solvent.6. The method of claim 1 , wherein the solvent comprises ethanol.7. A method claim 1 , comprising:contacting, with a solution, one or more of a surface used for food preparation, a surface used for food handling, a surface used for food packaging, equipment used for food preparation, equipment used for food handling and equipment used for food packaging,wherein the solution comprises at least one ethylene diamine tetra acidic acid (EDTA) salt and a solvent,wherein the at least one EDTA salt comprises tetra-sodium EDTA,wherein the solution is at a pH ...

HEMOSTATIC DEVICES AND METHODS OF USE

An anchorage device is provided that is configured to surround an implantable medical device. The anchorage device includes a substrate having a hemostatic agent and an active pharmaceutical ingredient selectively positioned on the substrate. Kits, systems and methods are disclosed. 1. An anchorage device configured to surround an implantable medical device , the anchorage device comprising:a substrate; anda hemostatic agent selectively positioned on the substrate.2. An anchorage device as recited in claim 1 , wherein the hemostatic agent is selectively positioned on the substrate such that hemostatic agent is targeted to a location of blood loss in a patient when the anchorage device is implanted within the patient.3. An anchorage device as recited in claim 1 , wherein the hemostatic agent is positioned on a bottom portion of the substrate.4. An anchorage device as recited in claim 1 , wherein the hemostatic agent is positioned on a bottom portion of the substrate and is spaced apart from a top portion of the substrate.5. An anchorage device as recited in claim 1 , wherein the hemostatic agent is positioned about a perimeter of the substrate.6. An anchorage device as recited in claim 1 , wherein the hemostatic agent is positioned about a perimeter of the substrate and is spaced apart from an interior portion of the substrate.7. An anchorage device as recited in claim 1 , wherein the substrate comprises a first piece and a second piece that is joined with the first piece claim 1 , the first piece and the second piece forming a pocket having a cavity and an opening that is in communication with the cavity claim 1 , the implantable medical device being configured to be inserted through the opening and into the cavity.8. An anchorage device as recited in claim 7 , wherein the first piece comprises the hemostatic agent and the second piece comprises an active pharmaceutical ingredient claim 7 , the second piece being free of the hemostatic agent.9. An anchorage device ...

WOUND DRESSING MATERIALS

A wound dressing material comprising: a wound dressing carrier, N-acetyl cysteine or a salt or derivative thereof, and a stabilized ascorbate. Suitably, the stabilized ascorbate comprises an ascorbate-2-polyphosphate. Also provided are wound dressings comprising the materials, methods of treatment with the materials, and methods of making the materials. 115.-. (canceled)16. A method of making a wound dressing , the method comprising the steps of:forming an aqueous dispersion, the aqueous dispersion comprising a bioabsorbable carrier material, N-acetyl cysteine or a salt thereof, a stabilized ascorbate, and an aqueous solvent, wherein a weight ratio of N-acetyl cysteine or a salt thereof to the stabilized ascorbate is from about 1:4 to about 4:1; andfreeze-drying or solvent-drying the aqueous dispersion to produce an active layer; the wound dressing comprises the active layer;', 'the active layer comprises a wound-facing side, the bioabsorbable carrier material, the N-acetyl cysteine or a salt thereof, and the stabilized ascorbate, where a weight ratio of N-acetyl cysteine or a salt thereof to the stabilized ascorbate is from about 1:4 to about 4:1 in the active layer; and', 'the stabilized ascorbate comprises a member selected from the group consisting of ascorbate 2-phosphate or polyphosphate compounds, trisodium L-ascorbyl-2-monophosphate, 2-phospho-L-ascorbic acid trisodium salt, magnesium ascorbyl phosphate (MAP), L-ascorbic acid mono(dihydrogen phosphate) magnesium salt, magnesium L-ascorbic acid-2-phosphate, trisodium L-ascorbyl-2-polyphosphate, and a combination of any two or more thereof., 'wherein'}17. The method of claim 16 , wherein the bioabsorbable carrier material is adapted to provide sustainable release of N-acetyl cysteine or a salt thereof and the stabilized ascorbate.18. The method of claim 16 , wherein the active layer is in the form of a sponge.19. The method of claim 16 , wherein the carrier material comprises oxidized cellulose.20. The method ...

BIOACTIVE MATERIAL COATED MEDICAL DEVICE

An implantable medical device includes a bioactive material coated on a contact surface. The contact surface and bioactive material each has a defined surface energy density comprising a polar component and a non-polar component. The polar components of the surface energies are substantially matched and the non-polar components of the surface energies are substantially matched so as to allow optimised bonding and elution of the material when in situ within a patient. A method for manufacturing the device is also provided. 1. An implantable medical device including at least one contact surface having a bioactive material coated directly thereon , wherein:the at least one contact surface has a defined surface energy density comprising a polar component and a non-polar component;the bioactive material has a defined surface energy density comprising a polar component and a non-polar component; andwherein the polar components of the surface energies of the at least one contact surface and of the bioactive material are substantially matched and wherein the non-polar components of the surface energies of the at least one contact surface and of the bioactive material are substantially matched.2. An implantable medical device according to wherein the polar components of the surface energies of the at least one contact surface and of the bioactive material are matched to within ±15 mN/m and wherein the non-polar components of the surface energies of the at least one contact surface and of the bioactive material are matched to within ±15 mN/m.3. An implantable medical device according to wherein the polar components of the surface energies of the at least one contact surface and of the bioactive material are matched to within ±10 mN/m and wherein the non-polar components of the surface energies of the at least one contact surface and of the bioactive material are matched to within ±10 mN/m.4. An implantable medical device according to wherein the polar components of the ...

HAEMOSTATIC MATERIAL

A haemostatic material that is effective at controlling the flow of blood from both standard and coagulopathic wound injuries that maintains a reduced compression time minimising the requirement for resuscitation fluids, and being easy and safe to use. 1. A haemostatic composition comprising a haemostat agent , a bioadhesive agent and an antifibrinolytic agent or derivative thereof.2. A composition according to claim 1 , wherein the antifibrinolytic agent comprises one or more selected from tranexamic acid claim 1 , aminocaproic acid claim 1 , aminomethylbenzoic acid claim 1 , aprotinin claim 1 , epsilon-aminocaproic acid and fibrinogen.3. A composition according to claim 1 , wherein the haemostat agent comprises one or more selected from oxidised regenerated cellulose claim 1 , kaolin claim 1 , gelatin claim 1 , calcium ions claim 1 , zeolite claim 1 , collagen claim 1 , chitosan or a chitosan salt.4. A composition according to claim 3 , wherein the haemostat agent comprises a chitosan salt.5. A composition according to claim 4 , wherein the chitosan salt comprises one or more selected from chitosan acetate claim 4 , chitosan lactate claim 4 , chitosan succinate claim 4 , chitosan malate claim 4 , chitosan sulphate or chitosan acrylate.6. A composition according to claim 5 , wherein the chitosan salt comprises lactate and/or chitosan succinate.7. A composition according to claim 1 , wherein the bioadhesive agent comprises one or more selected from a carbomer claim 1 , polyvinyl alcohol (PVA) claim 1 , polyvinylpyrrolidone (PVP) claim 1 , 2-acrylamido-2-methylpropane sulfonic acid claim 1 , or a high molecular weight acrylic acid polymer cross-linked with divinyl glycol or the salts of polyacrylic acid cross-linked with divinyl glycol.8. A composition according to claim 7 , wherein the bioadhesive agent comprises a cross-linked polymer of acrylic acid claim 7 , the polymer having a molecular weight of at least about 50 claim 7 ,000 g/mol.9. A composition according ...

用于治疗慢性伤口的组合物及制剂

本发明公开了用于治疗慢性伤口的组合物及制剂，用于治疗慢性伤口的组合物，按质量百分比由下述原料制成：精氨酸或精氨酸盐酸盐0.1％‑10％，海藻糖0.1％‑10％，黄原胶4.5％‑30％，丙二醇5％‑30％，水50％‑74.5％。试验证明，本发明的组合物及制剂，无刺激，吸水性强，能有效吸收渗出液，不与创面发生粘连，即移除时不会产生疼痛感，为伤口提供湿性愈合环境，有效促进创面愈合，并且制备方法简单，生产周期短，处方精简，成本低。

Nano non-woven containing antioxidant for wound dressing and method for preparing thereof

A nano non-woven fabric containing an antioxidant for wound dressing is provided to improve close adhesion to the skin and air permeability, to prevent contamination by bacterial invasion, and to suppress the production of active oxygen. A nano non-woven fabric for wound dressing contains an antioxidant using a bio-compatible polymer impregnated with N-acetyl-L-cysteine(NAC) as a support. The NAC containing polymer solution having a concentration of 3-20g/dl is then applied to a nano non-woven fabric by electrospinning. Both synthetic polymers or natural polymers can be used as the bio-compatible polymer. Examples of such polymers include polyvinyl alcohol, polyethylene oxide, polyethylene glycol, PLA, PGA, collagen, gelatin, alginate, alginic acid, chitosan, etc.

Tricalcium phosphate for use as implants

Ein resorbierbares, poröses Tricalciumphosphat, dessen Poren mit einer Mischung aus einem Antibiotikum und einem weiteren Füllstoff, insbesondere einer Aminosäure, ver­schlossen sind, ist besonders vorteilhaft bei der Herstel­lung von Knochenzementen zu verwenden. A resorbable, porous tricalcium phosphate, the pores of which are closed with a mixture of an antibiotic and a further filler, in particular an amino acid, can be used particularly advantageously in the production of bone cements.

TRICALCIUMPHOSPHATE FOR IMPLANTATION MATERIALS

Suture anchor with soft anchor of electrospun fibers

A flexible anchor for coupling a suture to a bone is provided. The anchor is composed of non-woven electrospun fibers and has an elongate tubular body that extends from a first end to a second end. The anchor is configured to receive a suture that enters the anchor through a first aperture and exits the anchor through a second aperture. When free ends of the suture are pulled, the anchor transitions from a first configuration to a second anchoring configuration.

One kind is based on galapectite and arginine modified poly ester urea urethane composite material and its preparation and application

本发明属于组织工程材料的技术领域，公开了一种基于埃洛石和精氨酸改性聚酯脲氨酯复合材料及其制备与应用。所述方法：1)在惰性氛围和搅拌的条件下，将聚己内酯二醇与六亚甲基二异氰酸酯在引发剂的作用下进行预聚反应，降温至40～70℃，加入L‑精氨酸‑1,8‑辛二醇酯溶液，继续反应5～10h，稀释，透析，冷冻干燥，获得聚酯脲氨酯材料；2)将聚酯脲氨酯材料溶解于有机溶剂中，加入埃洛石纳米管，分散均匀，成膜，获得复合材料。本发明的方法简单，所制备的复合材料具有良好的理化性能和生物学性能，可促进新骨的生成和骨缺损的修复并实现自身降解；用于骨组织工程材料领域。

Hemostatic material

本发明涉及止血材料，其有效地控制来自标准伤口损伤和凝血病伤口损伤二者的血流，同时保持降低的压迫时间，使对复苏流体的需求最小化，并且使用起来容易且安全。

The method for manufacturing and apparatus of polyurethane foam dressing

A method and an apparatus for manufacturing a polyurethane foam dressing are provided to improve a physical property of a foam dressing, and to promote mass production by improving productivity and process efficiency by a new simple and efficient manufacturing process. A method comprises the steps of: preparing non-porous waterproof polyurethane film layer; preparing polyurethane prepolymer; preparing polyurethane foam mixing liquid; obtaining a polyurethane layer in a gel state with a tack property; combining the polyurethane layer in a gel state and the polyurethane film layer; and winding the manufactured polyurethane foam dressing in a roll shape, and ripening it in a hot wind dryer.

Skin-friendly single-use product

The invention relates to a suction body component which is suitable for the durable storage of body fluids and is used to absorb, skin-friendly, single-use products. Said suction body component comprises a carrier material and a particulate super absorbing polymer material. The super absorbing polymer material has a core provided with an outer surface and at least one part of the outer surface thereof comprises a coating agent which is used to reduce the absorption rate of the core of the super absorbing polymer material. Said coating agent of the super absorbing polymer material comprises a skin-care product.

Antimicrobial compositions and methods for locking catheters

Antimicrobial compositions for use in locking catheters and other devices are provided. In some embodiments, the composition includes at least one alcohol, at least one biocidal agent which is not an alcohol, and one or more poloxamers; in other embodiments, the composition comprises at least one poloxamer and at least one alcohol. The composition can provide long-lasting antimicrobial activity. Methods of using the composition are also provided.

Antiseptic compositions, methods and systems

公开了包括至少一种EDTA盐的抗菌组合物。这些组合物具有广谱的抗微生物和抗真菌活性以及抗凝血特性。所述抗菌组合物还具有证实的穿透和分解微生物粘液，或生物膜的活性。它们对于人和医学应用是安全的，而且可用于预防感染，或减少已存在的或确定的感染的增殖，和/或消除已存在的或确定的感染。

Coating composition and medical device

The present invention provides a coating composition for drug eluting medical devices, which is capable of forming a medical agent coating layer that is not easily separated on the way to a target tissue during the delivery. This coating composition contains: a water-insoluble medical agent; at least one substance that is selected from the group consisting of hyaluronic acid, alkanoylated hyaluronic acid obtained by substituting at least some of hydrogen atoms in the hydroxy groups of hyaluronic acid with alkanoyl groups, and salts of hyaluronic acid and the alkanoylated hyaluronic acid; and at least one substance that is selected from the group consisting of amino acid esters and salts thereof.

Bioactive material coated medical device

Polyester with its main train having amino acid and contg. active drug, and its prepn. method

本发明公开了一种含有活性药物、主链中具有氨基酸的聚酯及其制备方法。该药物为具有如右结构通式的聚合物：R 1 代表丝氨酸、天冬氨酸、谷氨酸或赖氨酸；R 2 代表具有可反应基团的药物。该聚合物的制备包括交酯或内酯与含多官能团氨基酸的吗啉二酮衍生物的聚合、脱保护和与药物键合三个步骤。本发明将天然多官能团氨基酸无规地引入生物降解型聚酯中，避免了降解产物的抗原性，同时降解产物可被完全生物吸收。该聚酯含有羧基、羟基及氨基等活性基团，所得药物高分子可直接发挥作用，也可在降解后起作用。本发明可作为医疗器械的涂层，在改善器械的生物相容性的同时携带有针对性的药物，从而达到靶向持续给药的目的。也可制成植入体或其他制剂。

Patent FR2361437B1

Antimicrobial compositions and methods for locking catheters

Antimicrobial compositions for use in locking catheters and other devices are provided. In some embodiments, the composition includes at least one alcohol, at least one biocidal agent which is not an alcohol, and one or more poloxamers; in other embodiments, the composition comprises at least one poloxamer and at least one alcohol. The composition can provide long-lasting antimicrobial activity. Methods of using the composition are also provided.

Preparation method of biomedical antibacterial composite hydrogel

本发明属于水凝胶制备技术领域，具体的说是一种生物医用抗菌复合水凝胶的制备方法，该制备方法包括以下步骤：S1：原料准备：提前准备好制备所需要的原料；S2：进行制备：将称取的100g非离子型高分子溶于900g去离子水中，然后分别加入150g甲基丙烯酸羟乙酯(HEMA)、40gPEG、14g三羟甲基丙烷三丙烯酸酯和100g甘油，持续搅拌混合2h后加入1.66g光引发剂，继续搅拌30min，用紫外辐照60s后完成制备；S3：指标测试：对S2中所制备的生物医用抗菌复合水凝胶的理化性能等各项指标进行测试；基于非离子型亲水性高分子基材与抗菌剂复合，小分子亲水性单体交联形成互穿网络结构抗菌复合水凝胶提高水凝胶的力学性能，克服以往亲水性单体形成的水凝胶因吸水膨润后易碎的不足。

Antiseptic compositions, methods and systems

Process for manufacturing preparations promoting wound healing, and such preparations

A kind of preparation method of anti-oxidative nanofiber electrospinning film medical dressing

本发明提供一种抗氧化型纳米纤维电纺膜医用敷料的制备方法。所述医用敷料具体制备如下：将三氯甲烷与二甲基甲氨酰混合配置成混合溶剂，并将PCL颗粒溶解于上述混合溶剂中配置成PCL溶液，然后进行静电纺丝得到PCL纳米纤维电纺膜；取胶原蛋白粉末加到乙酸溶液中制成胶状均质溶液A，取Nac溶解于去离子水中得到溶液B，并将溶液A与溶液B混匀超声制成即为载有抗氧化药物Nac的胶原蛋白溶液，将其离心处理去除气泡后用加样枪均匀添加到PCL纳米纤维电纺膜上，依次经过冻干、交联剂溶液浸泡、冷冻干燥得到所述医用敷料。本发明制备的PCL纳米纤维电纺膜具有促进伤口愈合的能力，载有Nac药物的胶原蛋白作为抗氧化药物，有助于加强PCL膜促进愈合的作用。

Article for medical treatment

(57)【要約】 （修正有） 【課題】医療用物品、とくに人間または動物への流体の 投与を意図するカテーテルのような物品の抗菌剤処理を 提供する。 【解決手段】医療用物品、とくに中心静脈カテーテル は、アミノ酸または他のアミン置換有機酸の第四級アン モニウム塩以外の第四級化合物を含む第１の医療上許容 しうる抗菌剤およびアミノ酸または他のアミン置換有機 酸もしくは該アミノ酸または該他のアミン置換有機酸の 酸付加塩を含む第２の医療上許容しうる抗菌剤を放出可 能なように含む。該第１抗菌剤は好ましくはベンザルコ ニウムクロリドであり該第２抗菌剤は好ましくはＬ−ア ルギニンまたはＬ−アルギニン塩酸塩である。

Antimicrobial disposable absorbent articles.

Se describen los artículos absorbentes desechables que comprenden un material absorbente y una composición antimicrobiana. La composición antimicrobiana incluye un portador que comprende alcohol graso y un polímero de poli (alquilenoxi), y un agente antimicrobiano. La composición antimicrobiana puede ser recubierta sobre los sustratos componentes tales como materiales no tejidos y películas, que son incorporados dentro de los artículos absorbentes desechables, tales como pañales infantiles desechables, artículos de incontinencia para adultos, artículos para higiene femenina tales como toallas sanitarias, apósitos de heridas, vendajes, panti protectores y tampones, pañuelos para el cuidado personal y pañuelos domésticos para proporcionar control de olores, y control del crecimiento microbiano.

Coated implant

Reducing post-operative adhesion formation with intraperitoneal glutamine

Intraperitoneal administration of glutamine reduces post-operative adhesion formation.

Lens regeneration using endogenous stem/progenitor cells

The disclosure herein includes uses and systems for cataract removal and lens regeneration using endogenous stem cells that results in improved outcomes.

Skin-friendly disposable product

Modified osteogenic materials

包含胶原和去矿质骨颗粒的方法和产品。该产品可以含有最多20%(重量)的无机材料。该产品可以通过压缩致密。其中可以加入其它成骨因子、促细胞分裂剂、药物或抗生素。无机颗粒可以通过用钙结合蛋白或羟磷灰石结合蛋白、多肽或氨基酸预涂布,结合到有机基质上。该材料也表现出药物释放持续时间长的特性。本发明的主题是,用去矿质骨基质提高骨诱导速率和预见性。特别是,本发明涉及表现出成骨潜力增强的去矿质骨和钙盐或其它矿物盐的组合物。本发明还涉及包含大约60—90%(重量)去矿质骨的成骨组合物和能够诱导骨样结构的、包含载体和碱性磷酸酶的组合物。

Hemostasis device and application method

提供了一种设置成围绕可植入医疗装置的锚固装置。锚固装置包括基材和止血剂。基材包括第一片和与第一片接合的第二片。第一片包含止血剂，并且第二片包含活性药物成分。公开了试剂盒、系统和方法。

Pharmaceutical composition for wound healing containing substance P

本发明涉及一种用于伤口愈合的含有表面活性剂、抗氧化剂、增稠剂和P物质的药物组合物，涉及一种包括向受试者施用所述药物组合物步骤的用于伤口愈合的方法，以及一种用于伤口愈合的含有增稠剂、表面活性剂、抗氧化剂、和P物质的准药物组合物。本发明的药物组合物具有减少伤口大小和血管新生作用、显示真皮和表皮再生作用、成熟肉芽组织和产生胶原，因此可有利地用于愈合伤口。

Antibacterial disposable absorbent article

ELEMENT INTENDED FOR IMPLANTATION IN BONE TISSUE.

Pharmaceutical composition for wound healing containing substance p

Medical equipment

Topically administrable pharmaceutical compositions

The invention provides pharmaceutical compositions in solid or semi-solid form for topical application to external wounds to enhance tissue regeneration comprising calcium and potassium ions, physiologically acceptable counter ions therefor and one or more topical pharmaceutical carriers or excipients. The compositions include in particular, semi solid gels containing amino acids and solid gels adapted to release wound-healing substances.

Antiseptic compositions, methods and systems

Antiseptic compositions comprising at least one salt of EDTA are disclosed. These compositions have broad spectrum antimicrobial and antifungal activity together with anticoagulant properties. The antiseptic compositions also have demonstrated activity in penetrating and breaking down microbial slime, or biofilms. They are safe for human and medical uses, and may be used to prevent infection, or to reduce the proliferation of and/or eliminate existing or established infections.

Activated polymers binding biological molecules

The present invention relates to activated polymer substrates capable of binding functional biological molecules, to polymer substrates comprising bound and functional biological molecules, to devices comprising such substrates and to methods of producing them.

Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same

A medical device including an array of microneedles and a coating disposed on or within the microneedles and a method of making such a device are disclosed. The coating includes a peptide therapeutic agent and an amino acid. A method of stabilizing a peptide therapeutic agent with an amino acid on an array of microneedles is also disclosed. In some cases, the peptide therapeutic agent and the amino acid either both have a net positive charge or both have a net negative charge. In some cases, the peptide therapeutic agent is histidine.

Wound dressing materials

A wound dressing material comprising: a wound dressing carrier, N-acetyl cysteine or a salt or derivative thereof, and a stabilized ascorbate. Suitably, the stabilized ascorbate comprises an ascorbate-2-polyphosphate. Also provided are wound dressing comprising the materials, methods of treatment with the materials, and methods of making the materials.

Antiseptic compositions, procedures and systems

Una composición antiséptica que comprende al menos una sal de ácido etilendiamin tetraacético (EDTA) en solución, en la que al menos una sal de EDTA comprende al menos un EDTA trisódico y tetrasódico a una concentración de al menos el 0,01 % (p/v) y menos del 15 % (p/v), en la que la composición antiséptica tiene un efecto antimicrobiano contra un amplio espectro de microbios, en la que la composición antiséptica tiene un pH de al menos 9,5, y en la que la composición antiséptica está empaquetada y en forma estéril no pirogénica. An antiseptic composition comprising at least one salt of ethylenediamine tetraacetic acid (EDTA) in solution, wherein at least one salt of EDTA comprises at least one trisodium and tetrasodium EDTA at a concentration of at least 0.01% (w / v) and less than 15% (w / v), in which the antiseptic composition has an antimicrobial effect against a broad spectrum of microbes, in which the antiseptic composition has a pH of at least 9.5, and in which The antiseptic composition is packaged and in sterile non pyrogenic form.

A kind of composite antibacterial gel rubber material

本发明公开了一种复合抗菌凝胶材料，属于凝胶材料技术领域。本发明以阳离子交联剂壳聚糖、阴离子交联剂海藻酸钠、带负电荷的透明质酸等为原料，对芹菜进行浸泡后捣碎匀浆，进而便于溶出Fe 3+ ，再与保加利亚乳杆菌等混合发酵，可产生大量的细菌纤维素及生物有机质，添加的聚ε‑赖氨酸也可起到杀菌的作用，分解产生的氨基酸又可增强皮肤活力，优化使用体验；本发明对丝瓜和银耳进行处理，提高本凝胶材料的韧性，氧化的DOPA和未氧化的DOPA又可交联，用于皮肤和疤痕治疗，与细胞膜的脂质双分子层通过疏水作用相互结合，从分子层面上增加了其粘性。本发明解决了目前常用抗菌凝胶材料的透气性、粘结力不强问题。

Antimicrobial disposable absorbent articles

Disposable absorbent articles comprising an absorbent material and an antimicrobial composition are disclosed. The antimicrobial composition includes a carrier comprising fatty alcohol and a poly(alkyleneoxy) polymer, and an antimicrobial agent. The antimicrobial composition may be coated on to component substrates such as nonwovens and films, that are incorporated into disposable absorbent articles, such as disposable infant diapers, adult incontinence articles, feminine hygiene articles such as sanitary napkins, wound dressings, bandages, panty liners and tampons, personal care wipes and household wipes to provide odor control, and control of microbial growth.

Regenerated oxidized celulose based hemostatic materialcontaining antifibrolytic agents

In present invention oxidation method of viscon cellulose with NO 2 obtained H 3 PO 4 /HNO 3 is defined liquid and gas media. Regenerated oxidise cellulose (REOC in shorten term) contain in —COOH yields are standardised as 18.6-20.1 for textile, 19.8-21.5% for powder samples. Powder and textile (woven and fabric) products are impregnated 1.8-2.4% Ca +2 ion, 0-1.1% Na +1 ion, 0.8-1.5% tranexamic acid and 6-aminocaproic acid as antifibrinolytic. Obtained powder and gel products are impregnated Bi +3 , Zn +2 and Ag +1 ions for antiseptic purposes. Only Bismuth of them is shown antibacterial effects. Also the aim of present invention is haemostat antimicrobial properties during impregnation of Rifampicin, Gatifloxacin, Doxycycline, Levofloxacin, Lincomycin, Clindamycin, Ciprofloxacin. Haemostatic properties are indicated for all products and antimicrobial properties are shown for some samples. Cytotoxicity, sensitivity and irritation properties are determined in compliance of Pharmacopeias.

FOR IMPLANTATION IN BODY TISSUE Separate Bone Tissue, Dedicated Material

Use of antifibrinolytic agents for preparing sponges, compresses or dressings

Wound-healing pharmaceutical compositions in the form of a sterile powder based on amino acids and sodium hyaluronate

This invention relates to wound-healing pharmaceutical compositions in the form of a sterile powder based on amino acids and sodium hyaluronate.

Prebiotic compositions and methods for maintaining a healthy skin microbiota

A composition for providing or maintaining a healthy skin microbiota and methods of providing or maintaining a healthy skin microbiota are disclosed. The composition can be a prebiotic composition that can include a carrier and a skin microbiota balancing agent. In some aspects, the skin microbiota balancing agent can include at least one combination of carbohydrate sources including a first carbohydrate source and a second carbohydrate source. The skin microbiota balancing agent can be configured to provide at least two of the following desired ratios: a first desired ratio of Corynebaderium to Staphylococcus of 1.3, a second desired ratio of Corynebaderium to Micrococcus of 1.4, and a third desired ratio of Staphylococcus to Micrococcus of 1.1. The carbohydrate sources may be D-alanine, D-threonine, L-alanyl-glycine, succinic acid, a-keto-glutaric acid, m-tantaric acid, bromo succinic acid, mucic acid, phenylethyl-amine, inulin, oxalic acid, pectin, Tween 40 etc.

Method of obscuring immune recognition

The present invention provides a method of obscuring immune recognition of a transplant by a host mammal by encapsulating tissue suitable for use in a transplant within a hydrogel matrix, wherein the hydrogel matrix comprises gelatin, dextran, at least one nitric oxide inhibitor, and an effective amount of polar amino acids. The matrix binds to the cell surface proteins of the tissue and obscures recognition of the tissue by high affinity antibodies produced by the recipient of the transplant.

Method for producing thrombin-immobilized bioabsorbable sheet preparation

トロンビン固定化生体吸収性シート製剤の製造方法を提供する。有効成分としてトロンビン、柔軟化剤としてグリセロール、浸透化剤としてツイン80を含有し、場合によっては安定化剤としてヒスチジン及びトレハロースを含有するトロンビン充填液に、ポリグリコール酸からなる生体吸収性シートを浸漬し、トロンビンを該生体吸収性シート上に乾燥固定化する工程からなるトロンビン固定化生体吸収性シート製剤の製造方法、及び当該方法により得られるトロンビン固定化生体吸収性シート製剤。

Non-absorbent and absorbent articles for inhibiting the production of exoproteins

Non-absorbent and absorbent articles for inhibiting the production of exoproteins from Gram positive bacteria are disclosed. The non-absorbent and absorbent articles include an effective amount of a precursor compound having the general formula (I): wherein R1 is selected from the group consisting of formula (II) and formula (III); R7 is -OCH2-; X is 0 or 1; R5 is a substituted or unsubstituted aromatic ring or a monovalent saturated or unsaturated, substituted or unsubstituted, branched or straight chain hydrocarbyl moiety that may or may not be substituted with hetero atoms; R6 is selected from the group consisting of an amino acid, a methyl ester of an amino acid, and an ethyl ester of an amino acid; R2, R3, and R4 are independently selected from the group consisting of H, OH, COOH.

Element for implantation in bone tissue

Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same

A medical device including an array of microneedles and a coating disposed on or within the microneedles and a method of making such a device are disclosed. The coating includes a peptide therapeutic agent and an amino acid. A method of stabilizing a peptide therapeutic agent with an amino acid on an array of microneedles is also disclosed. In some cases, the peptide therapeutic agent and the amino acid either both have a net positive charge or both have a net negative charge. In some cases, the peptide therapeutic agent is histidine.

Method of obscuring immune recognition

The present invention provides a method of obscuring immune recognition of a transplant by a host mammal by encapsulating tissue suitable for use in a transplant within a hydrogel matrix, wherein the hydrogel matrix comprises gelatin, dextran, at least one nitric oxide inhibitor, and an effective amount of polar amino acids. The matrix binds to the cell surface proteins of the tissue and obscures recognition of the tissue by high affinity antibodies produced by the recipient of the transplant.

Artificial skin

Compositions for treating fungal and bacterial biofilms and methods of using the same

The disclosure provides compositions comprising amino acids, individually and in combination, and methods of making the compositions and methods of using the compositions as pharmaceutically active agents to, inter alia , treat disease in animals, including humans.

Biodegradable drug-loaded high polymer material stent and preparation method thereof

本发明公开了一种可生物降解载药高分子材料支架及其制备方法，属于高分子材料技术领域。本发明的可生物降解载药高分子材料支架，包括如下原料：甲壳质、磷酸钙、聚丙烯酸树脂、乙烯基吡咯烷酮、复合氨基酸、硫酸软骨素、治疗药物；其制备方法为：先制备一种网状结构支架，再将治疗药物经超声波雾化后喷涂在网状结构支架上面，从而得到可生物降解载药高分子材料支架。本发明的可生物降解载药高分子材料支架，拉伸强度可达72.5MPa，弯曲强度可达25MPa，表明力学性能良好；体外细胞毒性试验均为1级，表明对细胞活性影响较小，显示出优良的细胞相容性，具有重要的应用价值。

Preparation method of amino acid facing material of sanitary towel

本发明公开了一种氨基酸卫生巾覆面材料的制备方法，包括如下步骤：1)选取柞蚕茧和桑蚕茧按一定比例进行混合打碎制成蛋白原液；2)取蛋白原液通过分离技术分离出氨基酸原液；3)将氨基酸原液进行改性活化后纺丝制成氨基酸纤维；4)将氨基酸纤维通过珊瑚穿法制成具有柱形孔眼的覆面材料。本发明的一种氨基酸卫生巾覆面材料的制备方法制备出的氨基酸卫生巾覆面材料具有爽滑、柔顺、贴身、不过敏、抗螨抑菌防霉、去异味、透气性好、亲肤力明显、分解黑色素、营养价值高、对液体易吸收不反渗等特点，有效防止女性私处皮肤瘙痒、过敏症状的发生，具备滋养肌肤、平衡肌理、减轻炎症的作用。

COMPATIBLE MATERIAL WITH LIVING TISSUE AND BLOOD, AND METHOD FOR MANUFACTURING IT.

Method and hemostatic patch for effecting local hemostasis

In a method for effecting hemostasis of a bleeding wound, an antifibrinolytic agent is applied to a substrate and the substrate with the antifibrinolytic agent applied thereto is placed onto the bleeding wound. A hemostatic patch has a substrate that is impregnated with the antifibrinolytic agent and is preferably enclosed in a foil package and is ready to use when the package is opened.

Dosing regimens for treating hypoxia-associated tissue damage.

En el presente documento se describen métodos para el tratamiento del daño tisular asociado a hipoxia en sujetos; más particularmente, los métodos se refieren al tratamiento del daño tisular asociado a la hipoxia en un sujeto durante un procedimiento quirúrgico de acuerdo con regímenes de dosificación particulares; específicamente, los métodos se refieren a un esquema de dosificación que comprende dosificar a un sujeto durante un procedimiento quirúrgico en el que la primera dosis se administra al sujeto dentro de aproximadamente minutos después de una incisión quirúrgica inicial realizada durante el procedimiento quirúrgico.

MATERIAL COMPATIBLE WITH LIVING TISSUE AND BLOOD, AND METHOD FOR MANUFACTURING THE SAME

Fiber product having antibacterial and deodorant function

本发明提供把纤维素纤维或由该纤维素纤维构成的纤维制品与碱性氨基酸酯接触之后经加热处理得到的经数次洗涤也不丧失抗菌性的抗菌制品。抗菌性、除臭性和安全性优异的纤维制品，适用于存在使用时或保存时的细菌繁殖带来的，特别是恶臭成为问题的袜子、毛巾等抗菌制品，尤其适用于医疗或卫生用品。

Drug delivery compositions and methods

A drug delivery composition is disclosed which includes a triple salt proxy functional group and at least one amino acid functional group. A method of forming the drug delivery composition includes reacting a triple salt with at least one amino acid in an aqueous environment. A biodegradable fabric is disclosed which includes a polymerized structure of a triple salt proxy functional group and at least one amino acid functional group.

Hygiene tissue comprising microbe-inhibiting composition

本发明涉及卫生织物(1)，如湿巾、干拭巾、毛巾、贴片、小毛巾、纸巾等，所述的卫生织物(1)包含微生物抑制性组合物(8)，所述的微生物抑制性组合物(8)包含至少一种益生菌的胞外产物和有机酸和/或其盐形式的至少一种添加物，所述有机酸的至少一个pKa值不超过5.5。